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Sommario 
Introduzione: Il carcinoma ovarico di istotipo sieroso ad alto grado (HGSOC) rappresenta il più letale tra i 
tumori ginecologici, principalmente poiché viene spesso diagnosticato in fase avanzata di malattia e poiché  
dopo un’iniziale risposta alla prima linea di trattamento, si assiste all’insorgenza di recidive di malattia 
resistenti alle terapie convenzionali. La mancanza di marcatori diagnostici e prognostici affidabili, oltre che di 
terapie efficaci, rappresenta il principale ostacolo nella gestione clinica delle pazienti affette da HGSOC. Di 
recente è stata individuata una nuova classe di RNA non codificanti (ncRNA), comprendente i microRNA 
(miRNA) e i long non-coding RNA (LncRNA), con funzione di regolazione dell’espressione genica e con un 
importante ruolo nella biologia tumorale. In particolare, i ncRNA appaiono coinvolti nella progressione 
tumorale e nello sviluppo di chemioresistenza; ciò suggerisce un loro possibile ruolo come potenziali 
biomarcatori diagnostici, prognostici e predittivi di risposta al trattamento. Le condizioni ipossiche all’interno 
del microambiente tumorale, favorendone la neovascolarizzazione, rappresentano un evento essenziale che 
contribuisce allo sviluppo di un fenotipo più aggressivo dell’HGSOC. Recentemente, è stato identificato un 
gruppo di miRNA, nominati miRNA regolati dall’ipossia (HRM), che rappresentano degli elementi chiave in 
risposta alle condizioni ipossiche, essendo coinvolti nella regolazione di meccanismi che conferiscono una 
maggiore aggressività tumorale. La complessità dei processi coinvolti nella risposta all’ipossia nell’HGSOC 
non è stata ancora del tutto compresa. In questo contesto, la scoperta di biomarcatori utili dal punto di vista 
clinico per la selezione di pazienti affette da tumori caratterizzati da una spiccata ipossia, potrebbe favorire 
l’applicazione di trattamenti personalizzati. 
Scopi dello studio: Il mio progetto di dottorato è finalizzato allo studio di firme molecolari trascrizionali e 
post-trascrizionali caratterizzanti l’HGSOC, a livello sierico e tissutale. Nello specifico, la ricerca si è 
focalizzata sui seguenti punti: i) lo studio di miRNA circolanti, quali potenziali biomarcatori per la diagnosi 
precoce dell’HGSOC; ii) l’analisi dei profili di espressione di mRNA, miRNA e lncRNA dell’HGSOC e di 
tessuti sani di controllo; iii) la valutazione dell’espressione dei miRNA legati all’ipossia, nell’HGSOC e nei 
tessuti sani di controllo.  
Metodi: A partire da due coorti indipendenti, sono stati raccolti 168 sieri di pazienti affette da HGSOC e 65 
sieri appartenenti a donatori sani, che sono stati a loro volta stratificati in un training set, per l’individuazione 
di miRNA differenzialmente espressi tra le due popolazioni, e in un validation set, per la validazione dei dati. 
Prima dell’estrazione dell’RNA, ai campioni di siero sono stati aggiunti dieci oligonucleotidi sintetici ad RNA 
(RNA virali/C.Elegans) per consentire una normalizzazione accurata dei risultati. I profili di espressione dei 
miRNA sono stati ottenuti mediante tecnologia Agilent Microarray. Per la normalizzazione dei dati derivanti 
dall’analisi dei microarray è stato utilizzato un innovativo approccio statistico, basato sulla combinazione dei 
livelli degli oligo RNA sintetici e dei miRNA endogeni maggiormenti stabili all’interno del nostro sistema 
sperimentale. La validazione della firma molecolare nel training e nel validation set è stata ottenuta prima 
mediante PCR quantitativa (RT-qPCR) e successivamente confermata mediante una quantificazione 
assoluta, ottenuta con sistema droplet digital PCR (ddPCR).  
Inoltre, sono state raccolte 99 biopsie tumorali di HGSOC da pazienti a stadio III-IV di malattia, 76 delle quali 
appaiate ai campioni di siero. Essendo l’istogenesi di questa patologia ancora oggetto di dibattito, sono stati 
raccolti anche 30 campioni di epitelio ovarico sano e di epitelio di superficie tubarico, come controllo. I profili 
di espressione genica e dei miRNA sono stati ottenuti mediante tecnologia Agilent Microarray. I livelli di 
espressione dei miRNA, risultati differenzialmente espressi, sono stati associati alle variabili cliniche, quali la 
sopravvivenza globale (OS) e la sopravvivenza libera da progressione di malattia (PFS). Infine, un 
sottogruppo composto da 14 pazienti chemio-resistenti, 14 pazienti chemio-sensibili e 10 tessuti sani sono 
stati sequenziati allo scopo di individuare nuovi trascritti codificanti e non codificanti specifici dell’HGSOC. 
 
Risultati: Dall’analisi microarray 97 miRNA sono risultati significativamente differenzialmente espressi, tra i 
sieri di pazienti affette da HGSOC e i sieri di donatori sani (92 up-regolati e 5 down-regolati). Tra questi 
miRNA, i seguenti miR-1246, miR-595, miR-574-5p, miR-483-3p, miR-4290, miR-2278, miR-32, miR-4281 e 
miR-3148, che mostravano la più alta espressione media e il maggiore fold change misurati nel confronto tra 
i pazienti e i donatori sani, sono stati selezionati per ulteriori validazioni. In particolare, miR-1246, miR-595 e 
miR-2278 si sono confermati maggiormente espressi nel siero delle pazienti affette da HGSOC rispetto ai 
donatori sani, mediante PCR quantitativa (tutti i p-values<0.03), sia nel training che nel validation set. 
L’analisi della curva ROC (Receiver Operating Characteristic) ha mostrato miR-1246 come il miglior 
biomarcatore diagnostico, con una sensibilità dell’ 87%, una specificità del 77% ed un’accuratezza dell’ 84%. 
La quantificazione assoluta dei livelli circolanti del miR-1246, ottenuta mediante ddPCR, ha confermato il 
suo potenziale come biomarcatore diagnostico dell’HGSOC. 
L’analisi microarray dei profili tissutali dei miRNA ha rivelato un totale di 265 miRNA significativamente 
disregolati nei campioni di HGSOC rispetto ai tessuti sani (123 up-regolati e 142 down-regolati). Un gruppo 
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di 9 miRNA (miR-199b-5p, miR-423-5p miR-455-3p, miR-22-3p, miR-199a-3p, miR-15b-5p, miR-140-5p, 
miR-1246 e miR-320c) è emerso associato alla risposta al trattamento chemioterapico a base di platino e 
alla prognosi. In particolare, tra i campioni tumorali la up-regolazione del miR-1246 è risultata 
significativamente associata alla resistenza al platino e ad un breve OS e PFS (p-values<0.05). Le curve di 
sopravvivenza Kaplan Meier, basate sui livelli di espressione del miR-1246 misurati in RT-qPCR, hanno 
mostrato una significativa riduzione dell’OS e del PFS nei pazienti presentanti elevati livelli del miR-1246, 
rispetto ai soggetti con bassi livelli di espressione (p-value<0.001, HR=2.57; p-value=0.024, HR=1.68; 
rispettivamente). L’analisi multivariata ha confermato l’over-espressione del miR-1246 come fattore 
prognostico indipendente associato ad una riduzione dell’ OS e del PFS. Inoltre, i livelli del miR-1246 hanno 
mostrato una down-regolazione nei campioni di HGSOC rispetto ai campioni di HOSE (p-value<0.0001), ma 
sono risultati invariati rispetto ai campioni di epitelio tubarico, sia nelle analisi ottenute mediante microarray, 
che mediante RT-qPCR. Questo risultato rispecchia il trend di espressione globale dei miRNA emerso 
dall’analisi delle componenti principali (PCA), sui dati di microarray.  
Successivamente, ci siamo focalizzati sull’analisi di 16 miRNA appartenenti al gruppo dei miRNA regolati 
dall’ipossia, selezionati dopo un’ approfondita analisi della letteratura che mostrava il loro coinvolgimento in 
altri tipi di tumori solidi. Tra questi, il miR-210 e il cluster miR-27a-3p/23a-3p/24-3p si sono confermati, 
mediante RT-qPCR, significativamente up-regolati nei campioni di HGSOC rispetto ai tessuti normali (tutti i 
p-values≤0.002). L’ over-espressione del miR-23a-3p si è inoltre validata nel gruppo delle pazienti resistenti 
rispetto alle pazienti sensibili al trattamento chemioterapico a base di platino (p-value=0.03). Riguardo alla 
sopravvivenza, mediante analisi univariata, l’up-regolazione del miR-23a-3p è risultata associata ad una 
significativa riduzione del PFS (p-value=0.009, HR=1.8), ma non con una riduzione dell’OS. L’analisi 
multivariata ha inoltre confermato l’over-espressione del miR-23a-3p, come marcatore prognostico 
indipendente associato ad un breve PFS (p-value=0.01, HR=1.78). 
Infine, le analisi preliminari riguardanti il sequenziamento del trascrittoma ci hanno permesso di identificare 
1371 trascritti differenzialmente espressi tra campioni platino resistenti e platino sensibili. Tra loro, 125 
trascritti mostrano un completo appaiamento con trascritti noti, 686 sono potenziali nuove isoforme o 
mostrano una generica sovrapposizione con trascritti noti. Le rimanenti 560 sequenze, se validate, possono 
rappresentare nuovi trascritti intergenici o mostranti un appaiamento a livello esonico con sequenze di 
riferimento. 
 
Conclusioni: Questo studio mostra, per la prima volta, il miR-1246 come un potenziale biomarcatore sierico 
per la diagnosi dell’HGSOC, confermato da tre tecnologie (microarray, RT-qPCR and ddPCR) e validato in 
due coorti di pazienti indipendenti.  
L’analisi high-throughput ha individuato la maggior parte dei geni e dei miRNA disregolati nelle biopsie di  
HGSOC rispetto al tessuto sano di controllo. In particolare, i nostri risultati indicano un potenziale ruolo del 
miR-1246 come oncogene nella regolazione dei meccanismi responsabili della resistenza ai chemioterapici 
e come fattore prognostico di sopravvivenza delle pazienti affette da HGSOC.  
Le analisi riguardanti i miRNA associati all’ipossia suggeriscono un importante ruolo dei miRNA nella 
risposta alle condizioni ipossiche, che si verificano all’interno delle masse di HGSOC. In particolare, l’over-
espressione del miR-23a-3p  nel gruppo delle pazienti resistenti al platino evidenzia l’importanza dell’ipossia 
nell’insorgenza dei meccanismi di chemio-resistenza. Inoltre, l’over-espressione del miR-23a-3p potrebbe 
rappresentare un marcatore prognostico indipendente nelle pazienti affette da questa neoplasia. 
Infine, i risultati emersi dall’analisi preliminare dei dati riguardanti il sequenziamento del trascrittoma 
suggeriscono un marcato ruolo dei trascritti non-codificanti nei meccanismi di resistenza al platino 
nell’HGSOC. Gli eventuali trascritti validati verranno integrati con i profili di espressione dei geni e dei 
miRNA, precedentemente  ottenuti, con l’obiettivo di identificare circuiti tumorali associati con la risposta al 
trattamento ed alla prognosi, e per meglio comprendere i meccanismi molecolari che caratterizzano la 
progressione e l’adattamento dell’HGSOC al microambiente ipossico. 
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Abstract 
Introduction: High-grade serous ovarian carcinoma (HGSOC) is the most lethal gynecologic malignancy, 
mainly because the disease is frequently diagnosed at an advanced stage and is characterized by the early 
onset of chemoresistant recurrences. The lack of reliable diagnostic and prognostic markers, together with 
the lack of effective therapies, are the major obstacles to the clinical management of patients with HGSOC. 
A new class of non-coding RNAs (ncRNAs), such as microRNA (miRNAs) and long non-coding RNAs 
(LncRNAs), with a function of gene expression regulation, have been discovered to play an important role in 
human cancers. Increasing evidences suggest that ncRNAs are involved in cancer progression and 
development of chemoresistance, and support their role as potential diagnostic, predictive and prognostic 
biomarkers. The hypoxic condition within the tumor microenvironment, improving the tumor 
neovascularization, represents an essential event contributing to the development of a more aggressive 
HGSOC phenotype. Recently, a group of miRNAs, termed hypoxia regulated-miRNAs (HRMs), have been 
identified as key elements in response to hypoxia, regulating important mechanisms involved in tumor 
progression. The complexity of hypoxia molecular mechanisms has not been fully elucidated yet in HGSOC, 
therefore there is an urgent need to discover novel biomarkers clinically useful to select patients with hypoxic 
tumor, that may benefit of tailored treatments. 
Aims of the study: My PhD project aims at elucidating transcriptional and post-transcriptional signatures 
characterizing HGSOC, both at the serum and tissue levels. In detail, the research effort includes: i) the 
investigation of circulating miRNAs as novel potential biomarkers for HGSOC detection; ii) the analysis of 
mRNA, miRNA and lncRNA expression profiles of HGSOC and normal tissues; iii) the evaluation of hypoxia-
regulated miRNA expression in HGSOC and normal tissues. 
Methods: Sera from 168 HGSOC stage III-IV patients and 65 healthy donors were gathered together from 
two independent collections and stratified into a training set, for miRNA marker identification, and a validation 
set, for data validation. Nine synthetic viral/C.Elegans spike-in oligos were added to serum samples before 
RNA extraction, to allow accurate normalization. miRNA expression profiles were obtained using Agilent 
Microarray Technologies®. An innovative statistical approach for microarray data normalization, based on the 
contribute of spike-in oligos and the most invariant miRNAs, was developed to identify, in the training set, 
differentially expressed miRNAs. Signature validation in both the training and validation sets was performed 
by Real Time quantitative PCR (RT-qPCR) and confirmed by droplet digital PCR (ddPCR). 
A total of 99 tumor biopsies were collected from HGSOC stage III-IV patients, partially matched with the 
serum sample cohort (n=76). Thirty normal tissues were obtained from normal ovary (HOSE) and luminal 
fallopian tube surface epithelia, both representing the normal counterpart for HGSOC, whose histogenesis is 
still a matter of debate. Gene and miRNA expression profiles were obtained using Agilent Microarray 
Technologies®. miRNA expression levels were correlated with patient outcomes, as overall survival (OS) and 
progression-free survival (PFS). Additionally, a subgroup of 14 chemo-resistant and 14 chemo-sensitive 
HGSOC patients, together with 10 normal tissues were deep sequenced for the discovery of novel HGSOC 
specific coding and non-coding transcripts. 
 
Results: A panel of 97 miRNAs emerged significantly differentially expressed (92 up-regulated and five 
down-regulated) between sera of HGSOC patients and healthy donors by microarray analysis. Among them, 
the following miRNAs, i.e., miR-1246, miR-595, miR-574-5p, miR-483-3p, miR-4290, miR-2278, miR-32, 
miR-4281, and miR-3148, exhibiting both the highest average expression and log fold change measured in 
patients compared to healthy donors, were selected for further validation. miR-1246, miR-595 and miR-2278 
were confirmed as significantly over-expressed in serum of HGSOC patients compared to controls by RT-
qPCR (all p-values<0.03), in both the training and validation sets. Receiver Operating Characteristic (ROC) 
curve analysis revealed miR-1246 as the best diagnostic biomarker, with a sensitivity of 87%, a specificity of 
77% and an accuracy of 84%. The absolute quantification of circulating miR-1246 by ddPCR confirmed its 
potential as diagnostic biomarker in HGSOC.  
Microarray analysis of tissue miRNA profiling revealed a total of 265 miRNAs significantly dysregulated (123 
up-regulated and 142 down-regulated) in HGSOC compared to normal tissues. A group of nine miRNAs (i.e., 
miR-199b-5p, miR-423-5p miR-455-3p, miR-22-3p, miR-199a-3p, miR-15b-5p, miR-140-5p, miR-1246, and 
miR-320c) were associated with platinum response and prognosis. In particular, among tumor samples, miR-
1246 up-regulation was consistently associated with platinum-resistance, poor OS and poor PFS (p-
values<0.05). Kaplan-Meier survival curves, according to miR-1246 expression levels obtained by RT-qPCR, 
showed that OS and PFS decreased in patients with high miR-1246 expression compared to those with low 
miR-1246 expression (p-value<0.001, HR=2.57; p-value=0.024, HR=1.68; respectively). In addition, 
multivariate analysis revealed miR-1246 over-expression as an independent prognostic factor for poor OS 
and PFS (p-value=0.002, HR=2.31; p-value<0.05, HR=1.59; respectively). 
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Interestingly, compared to normal tissues, both with microarray and RT-qPCR techniques, miR-1246 showed 
a down-regulation compared to HOSEs (p-value<0.0001), but we did not detect a significantly differential 
expression compared to fallopian tubes. This result mirrors the global miRNA expression trend revealed by 
principal component analysis (PCA) on microarray data.  
Subsequently, we focused our analysis on a group of 16 miRNAs belonging to the group of hypoxia-
regulated miRNAs (HRMs) emerged from literature as relevant in other solid tumors. Among them, we 
confirmed miR-210 and miR-27a-3p/23a-3p/24-3p cluster as significantly up-regulated in HGSOC vs normal 
tissues by RT-qPCR (all p-values≤0.002). More interestingly, we validated the significant over-expression of 
miR-23a-3p in the group of patients resistant to platinum-based chemotherapy compared to platinum-
sensitive patients (p-value=0.03). In addition, in univariate survival analysis miR-23a-3p over-expression 
showed a significant correlation with decreased progression-free survival (p-value=0.009, HR=1.8), but not 
with overall survival variable. Importantly, miR-23a-3p over-expression has emerged as an independent 
prognostic marker for shortened progression-free survival in multivariate Cox regression analysis (p-
value=0.01, HR=1.78). 
Finally, the preliminary analysis of the transcriptome sequencing allowed us to identify 1371 transcripts 
differentially expressed between platinum-resistant and platinum-sensitive samples. Among them, 125 
transcripts showed a complete match of intron chain with known transcripts, 686 were potentially novel 
isoforms or showed a generic overlap with known transcripts. The remaining 560 sequences, if validated, 
could be novel intergenic transcripts or transcripts with an exonic overlap with reference ones.  
Conclusions: This study demonstrates, for the first time, miR-1246 as a potential diagnostic serum 
biomarker in HGSOC, as assessed by three independent technologies (microarray, RT-qPCR and ddPCR) 
and validated in two independent cohorts of patients.  
Moreover, high-throughput analysis reveals most of the gene and miRNA dysregulated in HGSOC biopsies 
compared to the normal counterpart. In particular, our findings indicate, for the first time, that miR-1246 over-
expression correlates with a platinum-resistant HGSOC phenotype and may constitute a novel prognostic 
factor for HGSOC patients.  
Furthermore, our results regarding HRMs suggest an important role of miRNAs in response to hypoxic 
conditions within HGSOC. Particularly, the miR-23a-3p over-expression in the group of platinum-resistance 
patients may contribute to explain the importance of hypoxia in HGSOC mechanism of drug resistance and 
could represent an independent prognostic marker for HGSOC patients. 
Lastly, preliminary data emerged from transcriptome analyses, suggesting a prominent non-coding role in 
HGSOC platinum resistance, will be integrated with gene and miRNA expression profiles previously 
obtained, with the aim to identify tumor circuits associated with response to treatment and prognosis, as well 
as to better elucidate the molecular mechanisms characterizing HGSOC progression and adaptation to 
hypoxic tumor microenvironment.  
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1. INTRODUCTION 
1.1 High-Grade Serous Epithelial Ovarian Cancer 
1.1.1 Background 
Ovarian cancer is the fifth leading cause of cancer death among women worldwide and the most 
lethal gynaecological malignancy. In the United States there are around 22,000 new cases of 
ovarian cancer diagnosed each year and more than 14,000 cancer-related deaths [Siegel RL et al. 
2016]. The majority of ovarian cancers are of epithelial origin, whereas fewer ovarian cancers 
develop from other cell types, such as sex-cord stromal, germ cell, or mixed cell-type tumors [Kalir 
T et al. 2013]. Currently, based on histopathology, immunohistochemistry and molecular genetic 
alterations, epithelial ovarian cancers (EOCs) are classified into five main subtypes: high-grade 
serous (70%), endometrioid (10%), clear cell (10%), mucinous (3%) and low-grade serous (<5%) 
[Prat J 2012]. Although traditionally referred to as a single entity, these EOC histotypes are 
essentially distinct diseases, as indicated by their differences in epidemiological and genetic risk 
factors, precursor lesions, patterns of spread, molecular events during oncogenesis, response to 
chemotherapy and prognosis. 
 
1.1.2 Clinicopathological features  
The most common histological EOC, the high-grade serous ovarian carcinoma (HGSOC), is 
generally diagnosed late (stage III-IV), when multiple synchronous tumor lesions are localized to 
the ovary, as well as in other anatomical sites within the peritoneum cavity. HGSOC develops 
rapidly, and is highly aggressive. The five-year survival rate for stage III-IV HGSOC is less than 
30%, as patients, despite an aggressive surgery and initial response to platinum agents, become 
progressively resistant and die from incurable disease. This neoplasm accounts for 90% of the 
deaths from ovarian cancer [Kurman RJ et al. 2016]. 
 
1.1.3 Morphological and immunohistochemical features 
Histologically, HGSOC is characterized by a heterogeneous architecture, composed by a solid 
mass of cells, including nested, papillary (micropapillary or macropapillary), glandular (slit-like or 
round spaces) and cribriform cells. Necrosis and multinucleate cells are often observed. Commonly 
psammoma bodies are present [Ramalingam P 2016]. It also exhibits moderate to marked nuclear 
atypia and a mitotic activity greater than 12/10 high-power microscopic fields (HPFs) [Malpica A et 
al. 2004]. Most HGSOCs show an intense immunoreactivity for p53, MIB1, WT1, bcl-2, c-kit, Her-2 
neu, estrogen receptor (ER), HLA-G and p16 [O'Neill CJ et al. 2005]. In particular, p53 
immunohistochemistry expression can exhibit two different patterns: the usual and the most 
commonly observed is characterized by strong diffuse nuclear staining in approximately 60% of 
cells or greater. This pattern correlates with a missense mutation. The other pattern is the 
complete absence of staining, which correlates with a nonsense mutation, resulting in a truncated 
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protein that is not detected by the p53 antibody [Yemelyanova A et al. 2011]. HGSOC also shows 
a high proliferation index, as indicated by an increased nuclear expression of Ki-67 [Prat J 2012] 
 
1.1.4 Molecular features 
Currently, our understanding of ovarian carcinogenesis and its role in tumor classification is mainly 
based on morphological features, but the importance of molecular classification is becoming 
increasingly evident. In recent years, the advent of next-generation sequencing and genome-wide 
analysis has greatly facilitated attempts to better characterize HGSOC molecular genetic profile 
and to discover novel HGSOC-associated genes. Recent studies have shown that HGSOCs are 
characterized by high genomic structural variations. They harbor frequent DNA amplifications and 
deletions, including heterozygous and homozygous loss and gene breakage [Kuo KT et al. 2009; 
Cancer Genome Atlas Research Network 2011], that make this cancer an extreme example of a 
chromosomally unstable (C-class) malignancy [Ciriello G et al. 2013]. In HGSOC, with the 
exception of TP53, which is inactivated in more than 95% of cases, somatic point mutations in 
other driver genes occur very infrequently. Importantly, there is a frequent inactivation (by 
germline, somatic and epigenetic mutations) of the BRCA1/2 genes involved in the DNA damage 
repair pathway. BRCA1 and BRCA2 are fundamental components of the homologous 
recombination DNA repair machinery, that is required to resolve DNA double-strand breaks (DSB) 
[Walsh T et al. 2010] . Initially, BRCA1 and BRCA2 gene mutations were observed in hereditary 
forms of HGSOC disease, that represent approximately 10%-15%, then sporadic forms (90%) 
were identified. Women with germline mutations in BRCA1 or BRCA2 have an increased risk 
(30%-70%) of developing HGSOC ovarian cancer by the age of 70. The sporadic forms of 
HGSOC, that harbor somatic mutation in BRCA1/2 suppressor genes, are defined BRCAness, to 
describe their genetic features and molecular behavior similar to HGSOC hereditary forms carrying 
germline mutations [Rigakos G and Razis E 2012]. As reported by Venkitaraman et al, the early 
loss of p53 function observed in sporadic form of cancers could create a permissive environment 
for the loss of BRCA1 or BRCA2 function [Venkitaraman AR 2002]. These studies suggest that 
loss of TP53 and BRCA inactivation are crucial initial steps of HGSOC carcinogenesis, followed by 
chromosomal instability, DNA copy number change, and segregation into molecular subtypes, as 
reported in the model schematically represented in Figure 1.1 [Bowtell DD 2010]. Among 
homozygous deletions, loci containing Rb1, CDKN2A/B, CSMD1, DOCK4, PTEN, and NF1 are 
most common [Vang R et al. 2009]. Additionally, HGSOC is characterized by high level of DNA 
copy number gains or losses, which include CCNE1 (cyclin E1), NOTCH3, AKT2, RSF1, and 
PIK3CA [Nakayama K et al. 2007]. In 2011, the Cancer Genome Atlas (TCGA) consortium 
performed a large-scale, multiplatform genomic profiling study to comprehensively characterize 
genomic and epigenetic abnormalities of HGSOC [Cancer Genome Atlas Research Network 2011]. 
A total of 489 clinically-annotated, stage II-IV, HGSOC tumor samples were analyzed for mRNA 
and microRNA expression, DNA copy number and DNA promoter methylation. Whole-exome DNA 
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sequencing was performed on 316 of these tumor samples. Missense or nonsense mutations in 
TP53 have been reported in more than 96% of HGSOC cases analyzed. BRCA1 and BRCA2 were 
found mutated in 22% of tumors, harboring a combination of germline and somatic mutations. 
Important focal DNA copy number alterations and promoter methylations were also detected in a 
total of 168 genes. The known tumor suppressor genes PTEN, RB1, and NF1 were in regions of 
homozygous deletions and were among the significantly mutated genes. Amplification of CCNE1 
was another frequent finding. NOTCH3 and FOXM1 signaling were also identified to be involved in 
HGSOC development [Cancer Genome Atlas Research Network 2011]. 
On the basis of gene expression cluster analysis of TCGA dataset, four robust transcriptional 
subtypes of HGSOC have been delineated and validated by gene expression profiling: 
Immunoreactive, Differentiated, Proliferative and Mesenchymal [Cancer Genome Atlas Research 
Network 2011; Tothill RW et al. 2008; Konecny GE et al. 2014]. These molecular subtypes were 
associated with distinct clinical outcomes and microenvironmental features. Surprisingly, however, 
not statistically significant difference in survival times among TCGA subtypes, in the 489 HGSOC 
patients analyzed, was observed. These molecular subtypes have not yet been integrated into the 
clinical setting.  
 
 
  
Figure 1.1: Schematic model of genetic events involved in the initiation and progression of high-
grade serous ovarian cancer. 
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1.1.5 Histogenesis 
Although HGSOC has been hypothesized to arise from the ovarian surface epithelium (OSE) or 
cortical inclusion cysts, multiple studies in the past three decades failed to identify a reliable 
precursor lesion of this disease. In the last decade, a growing body of evidence suggests that the 
majority of ovarian HGSOCs could develop from the epithelium of the fimbrial end of the fallopian 
tube. The initial evidence implicating the fimbrial epithelium has been described in women who had 
BRCA germline mutations and underwent prophylactic bilateral salpingo-oophorectomy. 
Pathologists, using the Sectioning and Extensively Examining the Fimbria (SEE-FIM) protocol, a 
new method of fallopian tube sampling, identified foci of small in situ serous tubal intraepithelial 
carcinoma (STIC) [Piek JM et al. 2001; Medeiros F et al. 2006; Crum CP et al. 2007]. Surprisingly, 
similar lesions were not detected in the ovaries of the same women. Even more, epidemiological 
studies showed that women who underwent prophylactic salpingectomy displayed a significantly 
decreased risk of HGSOC, compared with women that conserved fallopian tubes, further 
supporting the tubal origin of HGSOC [Ohman AW et al. 2014; Cherry C et al. 2013]. Additionally, 
another important evidence supporting the proposal that STIC could be the most likely HGSOC 
precursor was the identification of identical TP53 mutations, indicating a clonal relationship 
between the two malignancies [Kuhn E et al. 2012]. Further studies revealed the presence of STIC 
within the fallopian tubes, systematically examined, not only in those patients carrying BRCA1/2 
germline mutation, but also in 50% to 60% of patients with sporadic HGSOC [Przybycin CG et al. 
2010; Kindelberger DW et al. 2007]. In the percentage of women in which a STIC lesion was not 
identified, it has been hypothesized that a possible mechanism of HGSOC origin could be the 
implantation of the malignant cells from fimbrial tubal epithelium into the ovary (endosalpingiosis) 
or mesothelial surface invaginations (inclusion cysts). Then, they develop into a tumor mass that 
gives the impression that the tumor originated in the ovary (Figure 1.2) [Kurman RJ and Shih IeM 
2010]. 
On the other hand, in 2013, a group of researchers identified in a mouse model the presence of a 
stem cell niche of the ovarian surface epithelium (OSE). Those cells were localized in a 
transitional/junction area between OSE, mesothelium and tubal (oviductal) epithelium, at the hilum 
region of the mouse ovary. Those stem cell niches confined in that specific area may explained the 
susceptibility of transitional zones to malignant transformation and have important implications in 
HGSOC pathogenesis [Flesken-Nikitin A et al. 2013]. More recently, Kim et al have demonstrated, 
in mutant mice harboring TP53 mutation and underwent fallopian tube removal, that HGSOC 
developed from surface ovarian epithelium, leading to widespread metastases into the peritoneal 
cavity. They concluded that, despite ovarian epithelium cells intrinsically have less tumorigenic 
potential compared to fimbrial tubal epithelium cells, they can be an independent source of 
HGSOC [Kim J et al. 2015]. This evidence could clarify the origin of a subset of HGSOCs with no 
apparent STIC precursor lesions or involvement of fallopian tube. Therefore, at present, the 
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reliable site of origin of HGSOC is still debated. More experimental evidences are necessary to 
better elucidate the relative contribution of ovarian and fallopian sites to the genesis of HGSOC.  
 
 
 
Figure 1.2: Fallopian tube and ovarian surface epithelial hypotheses on origin of HGSOC. 
 
1.1.6 Diagnosis and screening 
Approximately 70% of HGSOC are diagnosed at advanced-stage, when the neoplasm has 
extensively spread throughout the peritoneal space, generating multiple metastasis by 
dissemination into the peritoneum (stage III) and to distant organs (stage IV). The often 
asymptomatic nature of HGSOC primary lesions and the dramatically rapid spread of this 
malignancy out of the pelvis make early-stage detection a highly rare event. At the moment, serum 
CA-125, in combination with ultrasound, is the most common used biomarker for HGSOC 
diagnosis. Since CA-125 is associated with a high false-positive rate among benign gynaecologic 
conditions, such as endometriosis, that mainly affects pre-menopausal women, its use is mainly 
reserved for EOC diagnosis in post-menopausal cases. However, in the current clinical setting, 
CA-125 is used as a serum biomarker in the differential diagnosis between EOC and benign pelvic 
masses also in pre-menopause women, despite its relatively low specificity. Furthermore, CA-125 
shows low sensitivity in identifying patients with early-stage EOC disease, being increased in only 
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50% of patients with stage I [Bandiera E et al. 2011]. In the last years, several investigations 
reported human epididymis protein 4 (HE4) as one of the most promising diagnostic serum marker 
for EOC, especially in combination with CA-125 [Drapkin R et al. 2005]. Based on these 
encouraging results, Moore et al. have developed the Risk of Ovarian Malignancy Algorithm 
(ROMA), a scoring system based on the dual marker combination of HE4 and CA-125, together 
with menopausal status, which showed an effective performance for the detection of EOC [Moore 
RG et al. 2009]. Accordingly, nowadays, ROMA is becoming more and more widespread in clinical 
practice for discrimination of benign masses from EOC. 
Over the past two decades, clinical screening trials, aimed at improving early-stage detection 
strategies of HGSOC, have failed to provide survival benefit. For instance, recent data from the 
Prostate, Lung, Colorectal and Ovarian (PLCO) trial, a large multicenter prospective study, 
demonstrated that, despite intensive annual screening for nearly 35,000 women with CA-125 and 
transvaginal ultrasound, 70% of the women presented with advanced stage disease, which was no 
different from unscreened populations [Buys SS et al. 2011]. Another recently published UK 
collaborative trial of ovarian cancer (UKCTOCS), analyzed more than 200,000 postmenopausal 
women for the predictive role of CA-125 alone or in combination with ultrasound scan. Results 
showed a modest reduction in mortality, by an estimated 20% after up of 14 years, with almost 
50% of ovarian cancer detected by multimodal screening or ultrasound alone [Jacobs IJ et al. 
2016]. Although additional analysis are expected to clarify better some points of the study, the 
modest reduction in mortality mirrors the limited sensitivity and specificity of currently known 
predictors of disease, like pelvic examination, CA-125 levels and transvaginal ultrasound, which 
finally impact on the ability to improve early disease detection. On the basis of current results, that 
have not shown any decrease in morbidity and mortality, widespread screening, using the 
aforementioned diagnostic methods, is not yet justified. To make a substantial impact on reducing 
the rate of mortality, the goal in screening should be the early detection of low-volume advanced 
stage, rather than early stage detection, with the use of highly sensitive and specific biomarkers 
expressed early in ovarian carcinogenesis [Menon U et al. 2009]. However, at present, the most 
effective strategy to reduce the mortality in HGSOC patients is the complete surgical removal of 
the ovaries and fallopian tubes in women who carry germline BRCA1/ BRCA2 mutations or with a 
strong family history of breast and/or ovarian cancer, as demonstrated by meta-analysis studies 
[Domchek SM et al. 2010; Rebbeck TR et al. 2009]. Moreover, as most hereditary HGSOC are 
thought to derive from fallopian tubes, based on the current understanding of HGSOC 
carcinogenesis, only salpingectomy is recommended in young BRCA1/BRCA2-mutant carriers to 
avoid the effects of early menopause [Kwon JS et al. 2013]. In this scenario, the advances in 
genome wide analyses could improve the discovery of new genetic abnormalities associated with 
HGSOC onset and then promote the identification of women with an increased genetic risk of 
developing HGSOC. 
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1.1.7 Standard management   
Considering that most HGSOCs are widespread throughout the abdomen at presentation, their 
frontline treatment consists of surgical tumor debulking, which typically includes a combination of 
peritoneal washing, hysterectomy, bilateral salpingo-oophorectomy, omentectectomy, lymph nodal 
and peritoneal biopsies, removing as much of tumor as possible. The main goals of HGSOC 
surgery are first to stage the tumor, defining how far it has spread from the ovaries, and secondly 
to perform an optimal-debulking achieving minimal residual tumor (RT< 1 cm). After surgery, the 
chemotherapy with a combination of platinum compounds and taxanes represent the gold standard 
first-line treatment for patients with HGSOC [McGuire WP et al. 1996; Piccart MJ et al. 2000]. 
Neoadjuvant chemotherapy with interval debulking surgery is another option for patients that 
present unresectable disease or medical comorbidities, and for whom primary surgery is not 
considered feasible. However, there are no strong evidences supporting that neoadjuvant 
chemotherapy before debulking surgery is a superior strategy in term of overall survival (OS) and 
progression-free survival (PFS) [Gultekin M et al. 2008]. Despite radical surgery and initial high 
response to first-line chemotherapy, patients frequently experience relapse, with disease that 
acquires increasing resistance to platinum agent at each recurrence. Recurrent ovarian cancer is 
classified as platinum resistant, defined as relapsing within 6 months, or platinum sensitive, defined 
as relapsing more than 6 months after completing initial platinum-based chemotherapy [Chien J et 
al. 2013]. Patients with platinum resistant disease are typically treated with other agents, such as 
pegylated liposomal doxorubicin (PLD), topotecan, gemcitabine, weekly paclitaxel, trabectidin or 
can be enrolled in clinical trials. Platinum-based therapy was introduced in clinical practice in the 
late 1970s, and subsequently, it was combined with taxanes. Over the past 40 years, only little 
improvements has been achieved in developing novel high-efficient compounds, with acceptable 
side effects. Thus, novel therapies are urgently required to improve outcomes of patients with 
HGSOC. Among the most promising targets identified in ovarian cancer, a leading role belongs to 
angiogenesis molecules. In recent years, several phase II studies have demonstrated the 
acceptable toxicity profile and therapeutic activity of Bevacizumab (BV), a monoclonal recombinant 
antibody that binds VEGF-A, in the treatment of relapsed ovarian cancer [Ellis LM and Hicklin DJ 
2008; Raspollini MR et al. 2005]. In 2011, two phase III trials, GOG-02188 and International 
Collaboration on Ovarian Neoplasms (ICON) 7, reported that the addition of bevacizumab to the 
combination of carboplatin and paclitaxel, followed by maintenance therapy significantly improved 
progression-free survival (PFS) (GOG-0218, HR: 0.72, p-value<0.001; ICON7, HR: 0.81, p-
value<0.004) [Burger RA et al. 2011; Perren TJ et al. 2011]. These results led the European 
Medicines Agency (EMA) to the approval of Bevacizumab in combination with carboplatin and 
paclitaxel as first-line treatment in EOC.  
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1.1.8 Novel treatment strategies 
Currently, novel agents are under investigation in HGSOC medical treatment. In particular, recent 
genome-wide studies have partially elucidated the mechanisms underlying chemoresistance, and 
the novel genetic mutations identified can be used as molecular targets for new selective 
pharmacological agents [Cancer Genome Atlas Research Network 2011; George J et al. 2013; 
Patch AM et al. 2015]. Different chemotherapeutic agents, such as platinum compounds, liposomal 
doxorubicin and trabectedin, are observed to have higher response rates in patients with BRCA 
mutation or with BRCAness phenotype [Yang D et al. 2011]. In this setting, also PARP inhibitors 
have been studied. PARPs, poly (ADP-ribose) polymerases (PARP), are a family of multifunctional 
enzymes that play an important role in the repair of DNA single-strand breaks. PARP inhibitors 
block the enzymatic activity of PARP by attaching to the enzyme’s active center and competing 
with its natural substrate [Rouleau M et al. 2010; Do K and Cehn AP 2012]. The inhibition of 
PARPs causes the accumulation of DNA single-strand breaks, leading to DNA double-strand 
breaks. Normal cells are able to repair this damage by homologous recombination but, in BRCA1/2 
mutation carriers, these lesions are not repaired, resulting in cell cycle arrest and cell death. The 
first-in-human clinical trial of the PARP inhibitor Olaparib has been conducted in patients with 
BRCA1/2-mutated advanced ovarian, breast and prostate cancers. The results from this phase I 
trial showed that the clinical benefits of Olaparib for BRCA-associated HGSOC was significantly 
greater in platinum-sensitive disease compared to platinum-resistance and refractory disease 
[Fong PC et al. 2009]. Olaparib demonstrated a very acceptable side effect profile when compared 
with conventional chemotherapies. A durable antitumor activity was found in cancer associated 
with the BRCA1 or BRCA2 mutation. These data indicate that using PARP inhibition to target a 
specific DNA-repair pathway has the necessary selectivity profile and a wide therapeutic window 
for BRCA-deficient cells, supporting the clinical relevance of the hypothesis that BRCA mutation-
associated cancers are susceptible to a synthetic lethal therapeutic approach [Ashworth A 2008; 
Kaelin WG 2005]. In the ICEBERG2 study, Audeh et al. provided positive proof of concept of the 
efficacy and tolerability of genetically targeted treatment with Olaparib in BRCA-mutated advanced 
ovarian cancer [Audeh MW et al. 2010]. In 2014, EMA approved Olaparib as monotherapy and, 
currently, it is the best-studied oral PARP inhibitor for maintenance treatment of platinum-sensitive 
recurrent BRCA-mutated (germ line and/or somatic) HGSOC with clinical response to platinum-
based chemotherapy. 
 
1.1.9 Prognostic and predictive factors  
Taking in consideration that the majority of patients with HGSOC presents with stage III-IV, it is 
well recognized that the amount of residual tumor after surgical staging and debulking is the most 
important prognostic factor. From a clinical perspective, advanced stage means more extensive 
disease that is less likely to be optimally debulked, compared to a tumor that is confined to the 
pelvis [Cho KR and Shih IeM 2009; Bristow RE et al. 2002]. In addition, it is important to consider 
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that the smaller is the residual tumor after surgery, the more effective chemotherapy is likely to be. 
Patients in whom all macroscopic disease can be completely resected (RT=0) have a significantly 
better prognosis [Eisenkop SM et al. 2006]. There is some prognostic stratification based on size of 
residual disease (i.e. RT<1 cm, 1-2 cm, >2 cm) in patients with macroscopic residual disease, but it 
is relatively minor [Hoskins WJ et al. 1994]. It is not clear at this time whether resectability reflects 
an intrinsically more favorable disease type, or whether increased surgical effort leads to better 
outcomes independently of intrinsic tumor characteristics. Actually, it has been showed that tumor 
molecular traits, as preoperative CA-125 and TP53 mutation, could influence the cytoreductibility of 
the tumor. In particular, Eltabbakh et al demonstrated that women affected by HGSOC, 
characterized by strong TP53 mutation, are significantly less likely to achieve complete debulking, 
than patients harboring tumors with moderate expression of p53 [Eltabbakh GH et al. 2004]. This 
evidence support the idea that genomic instability and specific genetic aberrations can lead to a 
more aggressive tumor phenotype, physically more invasive and less resectable. In the last years, 
an increasing number of studies have been focused on the identification of gene signatures able to 
explain and predict the response to therapy in HGSOC [Lloyd KL et al. 2015], but with 
unsatisfactory results. Nowadays, molecular markers of prognosis and response to therapy in 
HGSOC are relatively few and none has entered into routine clinical practice. Whereas, gene 
expression based tools, as MammaPrint and Oncotype DX, used to predict metastases and 
recurrence are already available for other disease, like breast and prostate cancer, respectively 
[Slodkowska EA and Ross JS 2009; Oncotype DX®]. More recently, studies with paired EOC tumor 
samples, collected at primary surgery and at following disease relapse, have provided some of the 
first insights into clonal variations and mechanisms of resistance. [Cooke SL et al. 2010; Stronach 
EA et al. 2011]. Interestingly, Marchini et al, analyzing matched tumor samples collected at first 
and second surgery, observed a low level (2%) of concordance between matched samples in 
terms of mutations in genes involved in key processes of tumor growth and drug resistance 
[Beltrame L et al. 2015]. Moreover, Patch et al, using whole-genome sequencing of tumor and 
germline DNA samples from 92 primary tumors and matched acquired resistant disease, observed 
several molecular events associated with platinum-resistance, including reversions of germline 
BRCA1 or BRCA2 alleles and recurrent promoter fusion associated with overexpression of the 
drug efflux pump MDR1 [Patch AM et al. 2015]. These results strongly support the necessity to 
analyze, at the molecular level, biopsies collected during HGSOC disease progression, to identify 
genomic features involved in drug resistance and to discover new molecular targets for the 
management of relapsed HGSOC patients.  
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1.1.10 Tumor microenvironment: Hypoxia 
Hypoxia is a common feature of tumor microenvironment, albeit with variable incidence and 
severity in different tumor types and within a single tumor. The development of rapidly expanding 
tumor masses, as HGSOCs, require the presence of a vascular network supplying oxygen and 
nutrients essential for their growth, although, when tumor cell proliferation exceed angiogenesis, 
the highly abnormal microvasculature fails to cover the oxygen requirement. As a consequence, 
tumor cells are exposed to an environment chronically deficient in O2 [Terraneo L et al. 2010]. 
Cellular adaptive responses to low oxygen microenvironment are mainly orchestrated by the 
activation of transcription factors called hypoxia-inducible factors (HIFs). Structurally, HIFs are 
heterodimeric proteins comprising an oxygen-regulated HIF-1α or HIF-2α subunit and a 
constitutively expressed HIF-1β subunit. While HIF1β is constitutively expressed, HIF-α levels are 
tightly regulated in response to changes in oxygen tension. In normoxia, HIF-α subunits are 
undetectable due to rapid hydroxylation by the von Hippel Lindau protein (pVHL) and to immediate 
degradation by the ubiquitin-proteasome system. Under hypoxic conditions, however, HIF-α 
proteins are stabilized from degradation for heterodimerization with HIF-1β. Once formed, this 
heterodimer binds to hypoxia response elements (HREs), in the promoter regions of specific 
hypoxia-sensitive genes, and thereby induce downstream transcription [Hashimoto T and 
Shibasaki F 2015]. The persistent exposure of tumor cell to hypoxia, or low oxygen tension, 
induces pro-survival changes in gene expression and in particular the activation of the angiogenic 
process, termed “angiogenic switch”. Angiogenesis, which is the process of developing new 
microvessels from pre-existing ones, is tightly regulated by a balance of pro-angiogenic mediators, 
like vascular endothelial growth factor (VEGF)-A and anti-angiogenic mediators, like angiopoietins 
(Ang1 and 2). HGSOCs express high levels of pro-angiogenic factors that contribute to the 
progression and aggressiveness of the disease [Gómez-Raposo C et al. 2009]. For this reason, 
important effort has gone into discovering novel anti-angiogenic agents in HGSOC, as 
Bevacizumab. As aforementioned, this immunoglobulin G1 monoclonal antibody targeting VEGF-A 
has been approved in clinical practice, in addition to platinum and taxane combination, in the first-
line setting and in maintenance therapy, in patients with advanced stage ovarian cancer. However, 
despite the presumed stability of the tumor endothelium, resistance to anti-VEGF agents has 
rapidly emerged in those patients. It has been hypothesize that the VEGF blockage could intensify 
the oxygen deprivation, leading to an increased hypoxic state in the tumor microenvironment. In 
support to this hypothesis, in-vivo studies have showed that the cleavage of blood vessels could 
further stimulate tumor cells to acquire invasive and metastatic features, showing an extremely 
capability of tumor cells to adapt and survive in hypoxic conditions [Paolicchi E et al. 2016; Choi HJ 
et al. 2015; Sennino B and McDonald DM 2012]. This tumor cell adaption to hypoxia, supported by 
a high genomic instability, is one of the main problem in fighting cancer. Indeed, hypoxia plays an 
active role in tumor progression, and confers increased resistance to standard chemo- and radio-
therapies in cancer cells [Cavazos DA and Brenner AJ 2015]. 
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1.2 Non-coding RNAs 
1.2.1 Background 
The completion of the Human Genome project revealed that the protein coding genes (around 
20000) cover less than 2% of the entire genome [ENCODE Project Consortium 2007]. This 
suggested that the majority of the genome, of mammals and other complex organisms, that was 
commonly defined ‘junk DNA’, due to its overwhelming burden of transposons, pseudogenes, and 
simple sequence repeats [de Koning AP et al. 2011], is transcribed into non-coding RNAs 
(ncRNAs), many of which are alternatively spliced and/or processed into smaller products. As 
represented in Figure 1.3, at present, ncRNAs are mainly categorized as “housekeeping”, a group 
of ncRNAs constitutively expressed, and regulatory ncRNAs. The first class includes ribosomal 
RNA (rRNA), transfer RNA (tRNA), splicing RNA (sRNA), nucleolar RNA (snoRNA) and small 
nuclear RNA (snRNA). Whereas, the regulatory ncRNA class includes different molecules that 
have crucial roles in the control, at various levels, of gene expression in physiology and 
development, including chromatin architecture/epigenetic memory, transcription, RNA splicing, 
editing, translation and turnover. Currently, regulatory ncRNAs include small ncRNAs (less than 
200 nucleotides), comprising small interfering RNA (siRNA), piwi-interacting RNA (piwiRNA), and 
microRNA (miRNA) [Kim VN et al. 2009]. In addition, more recently, another subtype of regulatory 
ncRNA, endogenous cellular RNAs of more than 200 nucleotides in length, termed long ncRNAs, 
has been included. Long ncRNAs can act in different ways in the cell; for instance, they regulate 
gene expression and influence protein localization [Kung JT et al. 2013; Gutschner T and 
Diederichs S 2012].  
 
                 
Figure 1.3: Non-coding RNAs in mammalian cells. 
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1.2.2 microRNAs 
microRNAs (miRNAs or miRs) are endogenous, small non-coding single-stranded RNAs of ~22 
nucleotides in length, highly conserved in a wide range of species, which function at post-
transcriptional level as negative regulators of gene expression. miRNAs were first described in 
1993, when a small RNA, lin-4, was discovered to negatively regulate LIN-14 levels, a protein 
involved in the developmental timing of the nematode C.Elegans [Lee RC et al. 1993]. However, 
the term ‘microRNA’ was only coined in 2001, when tens of small RNAs with regulatory potential 
were discovered in C.Elegans  [Lee RC and Ambros V 2001]. Since then, hundreds of similar small 
RNAs and number of different mechanisms for translational control by small RNAs in C.Elegans, 
Drosophila and mammals have been discovered. miRNAs play critical regulatory roles in the 
coordination of a wide variety of critical cellular processes like proliferation, differentiation, cell 
cycle regulation, apoptosis, stem cell maintenance, hypoxia and metabolism. miRNA expression is 
highly cell type and tissue specific, and it is present at different developmental stages, suggesting 
their important regulatory functions. Additionally, miRNAs are involved in pathological conditions 
like cardiovascular disease, obesity and cancer [Dalmay T and Edwards DR 2006; Hwang HW and 
Mendell JT 2006].  
To date, approximately 2,000 human hairpin precursor miRNAs, expressing 2,588 mature miRNA 
sequences have been annotated in the miRNA registry (http://www.mirbase.org/, miRBase release 
21, updated 2014), targeting and regulating the majority of coding genes [Kozomara A and 
Griffiths-Jones S 2014]. Typically, both the gene locus and precursor miRNA (pre-miRNA) of a 
miRNA is referred as "mir", while the mature miRNA product is designated "miR". Each miRNA is 
preceded by three letters specific for each species, for humans (Homo sapiens) those letters are 
"hsa" (e.g. hsa-miR-200). miRNAs have been numbered in order of discovery. Multiple miRNAs 
can be evolutionary related, with a nearly identical sequence, thus a letter after the number is used 
to differentiate among multiple members of the same family (e.g. hsa-miR-200a and hsa-miR-
200b). If different genomic loci produce identical miRNAs, additional number is given after the full 
name (e.g. hsa-miR-200-1 and hsa-miR-200-2). Two miRNAs, originating from opposing sides of 
the same double-stranded RNA, are named with a tag indicating from which mature sequence 
comes from (e.g hsa-miR-200a-3p from the 3’ arm and hsa-miR-200a-5p from the 5’ arm) 
(http://www.mirbase.org/). 
 
1.2.3 miRNA biogenesis and mechanisms of action 
miRNA biogenesis in human cells is a complex process comprising multiple steps, as illustrated in 
Figure 1.4. miRNAs can be organized as individual genes in intergenic regions or in genic regions 
(usually in introns or in non-coding exons), or localized as clusters representing miRNA families, 
which are commonly related in sequence and function. miRNAs are mainly transcribed by RNA 
polymerase II (rarely by RNA polymerase III) into long primary miRNA transcripts, either alone or in 
clusters, and folded into typical hairpin structurers of variable size, having a 5’ cap and a 3’ poly-A-
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tail, known as primary miRNAs (pri-miRNAs). Subsequently, these pri-miRNAs are recognized and 
cleaved in the nucleus by the Microprocessor complex, containing RNase III enzyme Drosha ant its 
cofactor RNA binding protein, DiGeorge Syndrome Critical Region 8 (DGCR8), resulting in 
individual stemloop hairpin precursor miRNAs (pre-miRNAs) [Lee Y et al. 2004]. Then, pre-
miRNAs are actively and rapidly exported from the nucleus to the cytoplasm by Exportin 5, a Rna-
GTP dependent nuclear export receptor. In the cytoplasm, pre-miRNAs are further processed by 
another RNase III enzyme, called Dicer, and its RNA binding co-factor TRBP (the human 
immunodeficiency virus transactivating response RNA-binding protein), into a transient 19–24 
nucleotide imperfect miRNA/miRNA* duplexes [Bohnsack MT et al. 2004]. Only one strand of the 
miRNA duplex (mature miRNA) is incorporated into a large protein complex, called RNA-induced 
silencing complex (RISC), containing Argonaute proteins (AGO1-AGO4). Each of the four AGO 
proteins possesses repressive capabilities, but only AGO2 has the potential to cleave target 
sequences due to its RNaseH-like domain [Peters L and Meister G 2007]. The mature miRNA 
leads RISC to cleave mRNA, to induce translational repression or to enhance mRNA degradation, 
depending on the degree of complementarity between the miRNA and its target [Hutvanger G and 
Zamore PD 2002]. The last two processes are more commonly associated with mismatched 
miRNA/target sequences that are the most likely scenario in mammals. Although the most frequent 
site of interaction is the 3’ untranslated region (UTR) of the target mRNA, several miRNAs have 
been described to bind to the open reading frame (ORF) sequences, as well as to the 5’UTR [Lytle 
JR et al. 2007]. This final interaction has been associated with activation, rather than repression. 
miRNAs can also bind directly to proteins, in particular RNA-binding proteins, in a sequence-
dependent manner and prevent these proteins from binding to their RNA targets. These decoy 
activities of miRNAs are RISC-independent [Eiring AM et al. 2010]. miRNAs can also regulate 
gene transcription by binding directly or by modulating methylation patterns at the target gene 
promoter level [Gonzalez S et al. 2008; Kim DH et al. 2008]. 
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      Figure 1.4: microRNA biogenesis and effector pathways.  
 
1.2.4 miRNA involvement in human cancer 
Cancer development and progression, associated with an abnormal alteration in several biologic 
mechanisms, such as, in particular, proliferation and apoptosis, not only lead to a misregulation of 
a plethora of protein-coding genes, but also to a global change in miRNA expression profile. The 
first evidence of miRNA involvement in human cancer disease has emerged from chronic 
lymphocitic leukemia studies. Croce et al identified the tumor suppressor miR-15/miR-16-1 cluster, 
located in a critical region of CLL frequently deleted [Cimmino A et al. 2005]. A couple of years 
later, all the known miRNA genes were mapped and many of them were found in genomic regions 
involved in cancer. In particular, miRNA genes were frequently located in regions showing 
chromosomal alterations, such as amplification or loss of heterozygosity and mutations, or in 
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fragile sites and common breakpoint areas near oncogenes or tumor suppressors genes [Calin GA 
et al. 2004]. In addition to structural genetic alterations, other mechanisms may affect miRNA 
dysregulation in cancer, as histone deacetylase inhibition and promoter hypermethylation. For 
instance, many genomic sequences of miRNA genes were found associated with CpG islands 
[Weber B et al. 2007]. Moreover, mutations in miRNA target site or in miRNA mature sequences 
can occur, inducing imperfect target recognition and inhibition of downstream protein complex 
processes. Deregulation in miRNA expression can be also affected by alteration in the miRNA 
biogenesis machinery. For instance, studies have reported a significant association between loss 
of Dicer and/or Drosha and outcome of patients, in several types of tumor, as lung cancer and 
ovarian carcinoma. Furthermore, miRNA expression profiles can be influenced by changes in the 
tumor microenvironment, such as tumor hypoxia [Kulshreshtha R et al. Mar 2007; Kulshreshtha R 
et al. Jun 2007; Giannakakis A et al. 2008; Kulshreshtha R et al. 2008; Crosby ME et al. 2009;]. On 
the regulation of gene expression, miRNAs may act as oncogenes or tumor suppressors, 
depending on whether they target tumor suppressor genes or oncogenes, respectively. 
Interestingly, the activity of miRNAs is high-context dependent. Indeed, the same miRNA can act 
as an oncogene in one type of cells and as a tumor suppressor in another, suggesting important 
regulatory functions [Croce CM 2009]. Accordingly, oncogene miRNAs are often overexpressed in 
some cancer types, whereas, in other cancers, when they act as tumor suppressor, they are 
commonly down-regulated. For example, miR-221/222 cluster, generally, is up-regulated and acts 
as oncogene targeting some important tumor suppressor genes (PTEN, p27 and p57), increasing 
proliferation of cancer cells in breast, lung and liver cancer. Conversely, the same cluster is down-
regulated in erythroblastic leukemias, where it targets c-KIT oncogene [Garofalo M et al. 2012]. In 
the last years, the advent of high-throughput profiling techniques, as miRNA microarrays and RNA-
Seq (RNA Sequencing), improved the miRNA expression analysis [Creighton CJ et al. 2009; 
Farazi TA et al. 2011]. In particular, It has been revealed a role of miRNAs in tumor progression, 
through targeting mRNAs involved in cell survival, proliferation, differentiation, angiogenesis and 
apoptosis, but specific miRNA pattern profiles have been discovered in different cancer types. 
Moreover, miRNA expression profiles have been correlated with clinical and biological features of 
tumors, including histological type, differentiation, aggressive behavior, prognosis and response to 
therapy. miRNA profiles can distinguish not only between normal and cancerous tissue and identify 
tissues of origin, but they can also discriminate different subtypes of a particular cancer or even 
specific oncogenic abnormalities: miRNAs, for example, are differentially expressed between basal 
and luminal breast cancer subtypes [Sempere LF et al. 2007] and can specifically classify estrogen 
receptor, progesterone receptor and HER2/neu receptor status [Iorio MV et al. 2005]. Even more 
importantly, several groups in recent years have reported how miRNA profiling can predict disease 
outcome or response to therapy [Li X et al. 2010; Caramuta S et al. 2010], for example miR-155 
overexpression and let-7a downregulation, which are able to predict poor disease outcome in lung 
cancers [Yanaihara N et al. 2006]. The evaluation of miRNA expression predicting the response to 
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specific drugs is another important goal, since it might help for a more accurate selection of 
patients potentially responsive to a specific therapy. For example, high miR-21 expression levels 
were detected to be associated with worse survival and poor response to adjuvant chemotherapy, 
both in colon adenocarcinomas [Schetter AJ et al. 2008] and in pancreatic cancer patients treated 
with gemcitabine [Giovannetti E et al. 2010]. In summary, the potential of miRNA signatures to 
distinguish between tumor and normal tissues, to discriminate between different subgroups of 
tumors and to predict outcome and response to therapy has focused scientists’ attention on these 
small molecules as potential clinical biomarkers, either diagnostic, predictive or prognostic. 
 
1.2.5 miRNAs in ovarian cancer tissues 
In the last years, several studies have demonstrated that several miRNAs are considerably 
dysregulated in advanced stage or high-grade ovarian cancers (OCs), suggesting their important 
roles in malignant transformation and tumor progression. Zhang et al reported that OC is 
characterized by massive miRNA deregulation, mainly due to genetic and epigenetic mechanisms 
[Zhang L et al. 2008]. Deletion occurs in up to 15% of genomic loci harboring miRNAs and 
epigenetic silencing is involved in 30% of down-regulated miRNAs, while mutations in cancer-
associated miRNAs are rare in OC [Katz B et al. 2015]. Actually, despite multiple studies showed 
altered miRNA expression pattern in OC tumor cells compared to normal tissues, there is only a 
little overlap between the results of these studies. These inconsistent data may be explained by 
some different aspects: the source of the samples used (flash frozen tissues, formalin fixed paraffin 
embedded tumors, cell line cultures), the inclusion criteria (histotype, stage, grade), the source of 
the normal tissues (ovarian surface epithelium brushing, ovarian biopsies, cell line cultures), the 
size of the study cohort and technical variables (sample management, RNA extraction protocol and 
platforms used for miRNA analyses). In 2007, Iorio et al published the first report regarding miRNA 
expression in OC compared to normal ovarian tissue. They found a total of 29 miRNAs 
dysregulated between groups. In particular, four miRNAs (miR-141, miR-200a, miR-200b, and 
miR-200c) emerged up-regulated, while 25 were down-regulated, including miR-199, miR-140, 
miR-145, and miR125b1 in cancer samples [Iorio MV et al. 2007]. Later, in 2008, Zhang et al, 
comparing 18 EOC cell lines and four immortalized cell lines derived from OSE, found four 
miRNAs over-expressed in EOC cell lines and 31 miRNAs down-regulated, including the tumor 
suppressor miRNAs let-7d and miR-127 [Zhang L et al. 2008]. These studies showed that miRNA 
expression profiles could distinguish malignant from normal ovarian surface epithelium. Since then, 
several studies have investigated the differences between the miRNA profiles of ovarian surface 
epithelium and OC, and the potential role of miRNAs in OC diagnosis, prognosis and treatment. 
Two of the most frequently identified deregulated miRNAs in OC are the miR-200 and the let-7 
families. The miR-200 family consists of five miRNAs (miR-200a, miR-200b, miR-200c, miR-141 
and miR-429) arranged in two clusters in the human genome. miR-200a, miR-200b and miR-429 
are located on chromosome 1, while miR-200c and miR-141 are on chromosome 12 [Park SM et 
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al. 2008]. In several studies, the expression of miR-200 family members has been associated with 
survival in EOC patients. In particular, Nam et al, using DNA microarray and northern blot 
analyses, identified 23 miRNAs differentially expressed between 20 serous OC tissues and eight 
normal ovarian tissues. They observed that high expression of miR-200a/b/c, miR-18, miR-93, 
miR-141, and miR-429 and low expression of let-7b and miR-199a significantly correlated with PFS 
and OS [Nam EJ et al. 2008]. Hu et al, in a study including 55 patients with stage III and IV of all 
histologic subtypes, showed a decreasing expression of miR-200a/b/c and miR-429 in patients with 
recurrence compared to recurrence free patients [Hu X et al. 2009]. Moreover, Marchini et al 
demonstrated that loss of miR-200c was associated with poor PFS and OS, in multivariate analysis 
of stage I EOC [Marchini S et al. 2011]. Currently, as emerged from the diverging results in above 
citied studies, the prognostic role of miR-200 family in EOC is not completely elucidated. The miR-
200 family members have been shown to play a critical role in the suppression of epithelial to 
mesenchymal transition (EMT). Park et al observed a positive correlation in the expression of E-
cadherin with the expression of miR-200c in ovarian cancer tissues. Actually, the over-expression 
of miR-200 a/b/c and/or miR-141 seems to down-regulate ZEB1 and ZEB2 levels, and leads to 
higher levels of E-cadherin and an epithelial phenotype [Park SM et al. 2008].  
The let-7 (lethal-7) family includes 13 human homologs tumor suppressor miRNAs located on nine 
different chromosomes. These loci have been identified situated in cancer-associated regions or in 
fragile sites and are typically down-regulated in OC [Dahiya N et al. 2008]. Let-7 suppresses 
multiple ovarian cancer oncogenes, which include KRAS, HRAS, c-Myc and HMGA-2 [Johnson SM 
et al. 2005; Büssing I et al. 2008]. Low expression of the let-7 family has been identified as a 
potential marker for early diagnosis, and associated with a decreased overall survival in several 
studies of OC [Yang N et al. 2008; Nam EJ et al. 2008] 
A number of studies attempted to identify specific miRNA expression profiles according to 
histological subtypes. Particularly, Iorio et al showed that miR-200a and miR-200c were over-
expressed in three types of ovarian cancer: serous, clear cell, and endometrioid. Whereas, miR-
200b and miR-141 were up-regulated in endometrioid and mucinous carcinoma [Iorio MV et al. 
2007]. Calura et al performed a miRNA array analysis of 257 stage I EOC of different  histotypes. 
They found high expression levels of miR-30a-3p and miR-30a-5p in clear cell carcinoma (CCC), 
whereas mucinous carcinoma (MC) expressed high levels of miR-192 and miR-194 [Calura E et al. 
2013]. Moreover, Vilming Elgaaen et al identified 12 miRNAs differently expressed between CCC 
and HGSOC. In particular, miR-509-3-5p, miR-509-5p, miR-509-3p, miR-508-5p, and miR-510 
were the most dysregulated miRNAs between histotypes [Vilming Elgaaen B et al. 2014]. 
Therefore, further investigations on the potential of these miRNAs to classify OC histological 
subtypes are needed.  
The most important milestone of integrated genomic analysis in HGSOC has been recently 
provided by TCGA on a total of 489 HGSOC samples. Cluster analysis on miRNA expression data 
defined three subtypes of HGSOC. Notably, miRNA subtype 1 overlapped the mRNA Proliferative 
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subtype and miRNA subtype 2 overlapped the mRNA Mesenchymal subtype, both above 
mentioned [Cancer Genome Atlas Research Network 2011]. TCGA has offered the foundations for 
many other studies investigating HGSOC prognosis. In particular, Yang et al, using the TCGA 
database, identified a miRNA-regulatory network that defined a robust integrated mesenchymal 
subtype associated with poor overall survival in 459 cases of serous ovarian cancer and 560 cases 
of an independent data cohort. Moreover, these analyses highlighted the central role of a miRNA 
regulatory network, consisting of eight miRNAs (miR-25, miR-29c, miR101, miR-128, miR-141, 
miR-182, miR-200a and miR-506) and predicted to regulate the 89% of targets in the 
mesenchymal subtype of HGSOC [Yang D et al. 2013]. Creighton et al, referring to the catalog of 
TCGA, developed an integrated analysis to improve the in silico miRNA-gene targeting predictions 
and to demonstrate the rich resource of TCGA in identifying miRNA candidates for functional 
targeting in cancer [Creighton CJ et al. 2012]. 
As aforementioned, it has been shown that miRNAs could play a crucial role in response to 
chemotherapy treatment in OC. A total of 27 miRNAs have been associated with responsiveness 
to chemotherapy [Hong L et al. 2013]. Yang et al. found that miR-214, which targets PTEN, is 
frequently expressed in ovarian cancer tissues and that let-7i, which enhances resensitization to 
platinum resistance, is expressed less in the same tissues [Yang N et al. 2008]. Aqeilan et al. 
found that miR-15 and miR-16 cause cellular resistance to many drugs, through targeting the BCL2 
gene [Aqeilan RI et al. 2010]. Leskelä et al showed that the miR-200 family (miR-141, miR-200a, 
miR-200b, miR-200c, and miR-42) is implicated in the response to paclitaxel treatment and 
progression-free survival, via tubulin III regulation. In particular, miR-200c is significantly 
associated with recurrence of ovarian cancer and miR-429 is associated with progression-free and 
overall survival rates [Leskelä S et al. 2011]. In a study conducted on a total of 198 serous ovarian 
cancer samples, Vecchione et al identified miR-217, miR-484 and miR-618 able to predict the 
chemoresistance of these tumors. They also demonstrated that miR-484 was able to improve 
chemosensitivity through the regulation of angiogenesis, by targeting VEGFR2 [Vecchione A et al. 
2013]. Additionally, a recent study has shown that let-7g selectively affects the sensitivity of a drug 
resistant ovarian cancer cell to taxanes by targeting IMP-1, an RNA binding protein which 
stabilizes MDR-1 (multidrug resistance-1), a membrane protein that pumps drugs into the 
extracellular space. Accordingly, the expression of let-7g resulted in a decrease in MDR-1 protein 
levels and sensitized the cells to taxane treatment [Boyerinas B et al. 2012] 
A novel potential treatment option for ovarian cancer includes supplementation of miRNAs that are 
down-regulated in cancer tissue for recovery of function and inhibition of the function of up-
regulated miRNAs by administration of complementary nucleic acids. Garzon et al showed that the 
effect of up-regulated oncomiR could be suppressed using an antagomir, an oligonucleotide 
complementary to the miRNA administered as an antisense oligonucleotide [Garzon R et al. 2010]. 
Dai et al established a therapy for ovarian cancer based on targeted delivery of miR-29a to cancer 
tissues for the purpose of reexpressing PTEN, a tumor suppressor. The potential antitumor effect 
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of a miR-29a-transfected chimera was apparently based on expression of downstream molecules 
and apoptosis of ovarian cancer cells [Dai F et al. 2012]. Cittelly et al found that recovery of the 
level of miR-200c by transfection, which is known to increase sensitivity to platinum-based 
anticancer drugs, suppressed carcinogenesis and decreased the number of cancer cells. The 
recovery of miR-200c immediately before highly cytotoxic chemotherapy improves the treatment 
response or reduces the effective dose of the anticancer drugs [Cittelly DM et al. 2012]. These 
functional studies suggest that the modulation of miRNA misexpression is an attractive target for 
cancer therapeutics. However, before proceeding with clinical trials, additional analyses and 
validations of the administration of complementary nucleic acids, as miRNA mimics and antisense 
mRNAs, both in-vitro and in-vivo, are necessary to better verify their efficacy. 
 
1.2.6 Circulating miRNAs in cancer 
In the last years, several investigations have discovered that miRNAs can move from tumor tissue 
to blood circulation. Circulating miRNAs are extremely stable and can withstand multiple freeze-
thaw cycles, long period of storage, temperature and pH changes and show resistance to blood 
RNase activity [Chen X et al. 2008]. Indeed, serum and other body fluids are known to contain 
ribonucleases, but the majority of miRNAs are packaged with ribonucleoproteins, as Argonaute2 
proteins, protecting them against enzyme digestion. Furthermore, several studies have identified 
miRNAs complexed with lipoproteins and two types of cell-derived lipid vesicles: exosomes and 
microvesicles. Lipoproteins are complexes that consist of a lipid core surrounded by a shell of 
apolipoproteins that allow the lipids to travel in the bloodstream. Exosomes are small (30-100 nm) 
lipoprotein vesicles, that are released into the extracellular environment when endosomally-derived 
multivesicular bodies fuse with the plasma membrane. Microvesicles are larger than exosomes 
(100nm-1µm) and are released from the plasma membrane of stimulated cells [Etheridge A et al. 
2011]. Lawrie et al detected, for the first time, the presence of serum miRNAs in cancer patients. 
They found that miR-155, miR-210, and miR-21 were higher in serum from patients with diffuse 
large B-cell lymphoma, and high level of miR-21 expression was associated with patients’ relapse 
free survival [Lawrie CH et al. 2008]. Subsequently, serum miRNAs were tested as biomarkers for 
disease monitoring in prostate cancer, and for the early detection both in the lung and colorectal 
carcinomas. Moreover, similar studies have been performed in many types of cancer including 
gastric, breast and ovarian cancer [Zhu C et al. 2014; Shimomura A et al. 2016; Nowak M et al. 
2015]. Currently, miR-test, based on a serum signature of 13 miRNAs, represents one of the most 
promising tool for lung cancer screening in high-risk individuals [Montani F et al. 2015] 
 
1.2.7 Circulating miRNAs in ovarian cancer 
Given the stability of miRNAs in the peripheral blood and tumor-specific miRNA profiling, 
circulatory miRNAs may be superior potential biomarkers for ovarian cancer diagnosis and 
prognosis than tissue miRNAs. In recent years, several circulating miRNAs have been identified as 
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biomarkers with implications in ovarian cancer early detection, association with clinicopathological 
features and prognosis. The differentially expressed miRNAs of each study are summarized in 
Table 1.1. The first study in OC was performed by Taylor et al in 2008, investigating exosomes 
from the peripheral blood circulation of ovarian cancer patients. They found that the eight miRNAs 
over-expressed in serous ovarian cancer tissue (miR-21, miR-141, miR-200a, miR-200b, miR-
200c, miR-203, miR-205 and miR-214) were also elevated in serum-derived exosomes. These 
circulating miRNA levels were also significantly higher compared with those detected in patients 
with benign disease [Taylor DD and Gercel-Taylor C 2008]. In another study, Resnick et al 
empirically selected  21 miRNAs from the OC tissue profile. They identified five miRNA significantly 
over-expressed (miR-21, miR-29a, miR-92, miR-93 and miR-126) and three under-expressed 
(miR-127, miR-155 and miR-99b) in the serum of OC patients compared with controls [Resnick KE 
et al. 2009]. Kan et al confirmed the overexpression of miR-200a, miR-200b and miR-200c in 
serum of serous OC patients, compared to controls. Moreover, a multivariate model combining 
miR-200b and miR-200c was able to discriminate patients with HGSOC from age-matched healthy 
donors [Kan CW et al. 2012] Another study on serous OC was conducted by Chung et al using 
microarray and RT-qPCR. They detected four serum miRNAs (miR-132, miR-26a, let-7b, miR-145) 
significantly down-regulated in OC patients compared to controls, making these miRNAs potential 
candidates for novel diagnostic biomarkers [Chung YW et al. 2013]. Zheng et al performed a study 
on a large cohort of plasma samples of 360 OC patients and 200 healthy controls, grouped into 
screening, training and validation sets. Using TaqMan low-density array, they identified higher miR-
205 and lower let-7f expression in plasma  samples from tumor patients compared to controls. 
Moreover, the two miRNA combination provided a higher diagnostic accuracy for OC, especially in 
patients with stage I disease [Zheng H et al. 2013]. For the first time, Shapira et al conducted a 
study focused on protein-bound miRNA in plasma free of cellular debris, microvesicles or 
exosomes. A total of 19 miRNAs emerged down-regulated, while three were up-regulated in 
serous OC compared to controls. In particular, six miRNAs (miR-106b, miR-126, miR-150, miR-17, 
miR-20a and miR-92a) resulted significantly decreased in OC patients [Shapira I et al. 2014]. 
Recently, Langhe et al, using the Exiqon discovery platform, identified a panel of four miRNAs (let-
7i-5p, miR-122, miR-152-5p and miR-25-3p) significantly down-regulated in cancer patients, 
compared to patients with benign serous cystoadenomas [Langhe R et al. 2015].  Recently, Zuberi 
et al confirmed the members of the miR-200 family overexpressed and associated with tumor 
progression in OC samples [Zuberi M et al. 2015]. Moreover, the same group investigated the 
expression level of miR-199a by RT-qPCR. A significant down-regulation of miR-199a levels has 
emerged in the group of tumor patients compared with matched normal controls and its expression 
were significantly associated with more aggressive clinicopathological features [Zuberi M et al. 
2016]. More recently, serum levels of exosomal miR-373, miR-200a, miR-200b and miR-200c were 
found significantly higher in OC patients than healthy donors, by TaqMan MicroRNA assay. In 
particular, members of miRNA-200 family were able to discriminate between malignant and benign 
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ovarian tumors. Moreover, miR-200b and miR-200c were observed significantly increased in 
advanced stage OC, suggesting a possible involvement in tumor progression [Meng X et al. 2016]. 
The above mentioned studies suggest that circulating miRNAs may be powerful diagnostic and 
prognostic tools in ovarian cancer patients. However, at present, the inconsistent results across 
studies do not support their application as biomarkers in daily clinical ovarian cancer management. 
Studies performed in large well-characterized cohorts and independently validated are urgently 
needed, before any clinical value of circulating miRNAs can be evaluated. 
 
Table 1.1: Studies on circulating miRNAs as potential biomarkers of ovarian cancer 
 
Authors Years Type of tissue Histology Control 
Up-regulated 
miRNAs 
Down-regulated 
miRNAs 
Discovery 
platform 
Taylor et al. 2008 Serum exosome Serous 
Benign 
ovarian tumor 
miR-21,miR-141, 
miR-200a,b,c, 
miR-203, 
miR-205,miR-214 
─ Custom microRNA arrays 
Resnick  et al. 2009 Serum EOC Healthy control 
miR-21,miR-29a, 
miR-92, miR-93, 
miR-126 
miR-127, miR-155  
miR-99b 
TaqMan array 
RT-qPCR 
Hausler et al. 2010 Whole blood EOC Healthy control miR-30c1 
miR-342-3p 
miR-181a 
miR-450-p 
Geniom Biochip 
Kan et al. 2012 Serum HGSC HOSE/healthy control miR-200a,b,c ─ TaqMan assays 
Chung et al. 2013 
Serum 
(tissue and 
ascites) 
Serous Healthy control ─ 
miR-132 
miR-26a 
let-7b,miR-145 
Microarray 
RT-qPCR 
Zheng et al. 2013 Plasma EOC Healthy control miR-205 let-7f 
TaqMan Low-
density array  
 RT-qPCR 
Xu et al. 2013 Serum EOC Healthy control miR-21 ─ RT-qPCR 
Hong et al. 2013 Serum EOC Healthy control miR-221 ─ RT-qPCR 
Ji et al. 2014 Serum EOC 
Healthy 
control/benign 
ovarian tumors 
miR-22, miR-93 ─ Solexa sequencing 
Shapira et al. 2014 Plasma serous 
Healthy 
control/benign 
ovarian tumor 
─ 
miR106a,126,146
a,150,16,17,19b, 
20a,223,24,92a 
TaqMan Open 
Array MicroRNA 
Langhe et al. 2015 Serum serous Benign ovarian tumor ─ 
let-7i-5p,miR-122, 
miR-152-5p, 
miR-25-3p 
Exiqon panel 
RT-qPCR 
Gao et al. 2015 Serum EOC/ borderline 
Healthy 
control miR-200c,miR-141 ─ RT-qPCR 
Zuberi et al. 2015 Serum EOC Healthy control miR-200a,b,c ─ RT-qPCR 
Zuberi et al. 2016 Serum EOC Healthy control ─ miR-199a RT-qPCR 
Meng et al. 2016 Serum exosomes EOC 
Healthy 
control 
miR-373, miR-
200a,b,c ─ TaqMan assay 
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1.2.8 miRNA involvement in hypoxic condition 
Over the past few years, the “classic” protein coding hypoxia-regulated genes have been joined by 
specific miRNAs, thus adding a new paradigm of gene expression regulation in an already complex 
process and providing an additional link between tumor-specific stress factor and gene expression 
control. The first evidence of an hypoxic cancer-related miRNA signature was described by 
Kulshreshtha et al. They reported a group of miRNAs that included: miR-21,23a, 23b, 24, 26a, 26b, 
27a, 30b, 93, 103, 106a, 107, 125b, 181a, 181b, 181c, 192, 195, 210 and 213, which were 
consistently expressed in response to low oxygen tension, in breast and colon cancer cell lines. 
[Kulshreshtha R et al. 2007 Mar]. These miRNAs, differently expressed in response to hypoxia, 
have been collectively termed “hypoxia-regulated miRNAs” (HRMs) or later, “hypoxamiRs”. During 
the last years, numerous studies have reported different hypoxic miRNA signatures, comprising 
more than 90 HRMs, in a variety of cellular types and conditions. However, a significant number of 
HRM lists were not consistent across studies. This discrepancy was not surprising and could be 
attributable to a combination of technical variables, as the sensitivity of analysis methods, the 
duration and severity of oxygen deprivation, the cellular types and context. To date, miR-210 
represents a unique HRM consistently reported up-regulated from multiple independent research 
groups, being robustly induced by HIF-1α, in a wide range of cell types in response to hypoxia 
[Chan SY and Loscalzo J 2010]. Furthermore, miR-210 has been identified over-expressed in a 
variety of cancer, including breast, glioblastoma, lung, melanoma, prostate and many others, with 
the exception of ovarian cancer, in which has been reported a frequent gene deletion, by 
Giannakakis et al and Vaksman et al [Giannakakis A et al. 2008; Vaksman O et al. 2011]. In a 
large genome-wide microarray profiling study, conducted by Volinia et al on a total of 540 tumor 
samples (including breast, lung, colon, stomach, prostate carcinomas and pancreatic endocrine 
tumors), a “common signature” of abnormally expressed miRNAs has emerged, compared to 
normal tissues [Volinia S et al. 2006]. In order to identify a possible correlation between the miRNA 
signature expression in solid tumors and in hypoxic condition, Kulshreshtha et al examined the 
pattern of miRNA changes during hypoxia within the same miRNA profile obtained by microarray. 
Notably, most of HRMs resulted overexpressed in at least some of analyzed tumors [Kulshreshtha 
et al. Mar 2007]. This result suggested that hypoxia may contribute to miRNA dysregulation in 
different types of cancer. In cellular adaptation to hypoxia, HRMs can play different roles, targeting 
important gene transcripts implicated in a wide range of processes, as metabolic reprogramming, 
DNA repair, apoptosis and angiogenesis, among many other cellular adaptations to low oxygen 
availability. Many HRMs can play an active role on HIF and promote its expression and/or activity. 
Some of these miRNAs are also direct transcriptional targets of HIF itself during hypoxia, resulting 
in a positive-feedback loops. For example, miR-210 is potently induced by HIF in response to 
hypoxia, and could repress glycerol-3-phosphate dehydrogenase 1-like (GPD1L), which, in turn, 
stabilize HIF1 by reducing hyperhydroxylation [Kelly TJ et al. 2011]. Moreover, the down-
expression of miR-20b, miR-199a, and cluster miR-17-92 in hypoxia conditions, stabilize HIF1, 
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because these HRMs are able to repress the expression of HIF1 through direct targeting. In 
hypoxic endothelial cells, miR-424 is able to stabilize HIF1, suppressing cullin 2 (CUL2), a 
scaffolding protein critical to the assembly of the ubiquitin ligase [Ghosh G et al. 2010]. Many other 
HRMs, that contain hypoxia responsive elements (HREs) in their promoter regions, and thus being 
induced by HIF-dependent manner, also coordinate important adaptive response to hypoxia 
downstream of HIF. For instance, both miR-210 and miR-373, direct transcriptional targets of HIF, 
alter DNA repair responses by decreasing levels of DNA repair proteins, such as RAD52 and 
RAD23B, key members of homology-dependent repair (HDR) and nucleotide excision repair (NER) 
pathways [Crosby ME et al. 2009]. These results describe a role of HRMs in the regulation of DNA 
repair and genetic instability in response to hypoxia in cancer. In the last years, emerging 
evidences showed the activation of HIF-independent pathways in the adaptive cell response to low 
oxygen tension. Particularly, several other transcription factors (TFs), such as p53, NF-kB and 
PU.1 also regulate the transcription of specific miRNA involved in cell cycle arrest, inflammation 
response or reinforcement of HIF stabilization [Cummis EP and Taylor CT 2005]. As mentioned 
above, multiple miRNAs are known or suspected to be involved in various steps of angiogenesis 
response. One of the most important miRNA target of angiogenesis is VEGF. Experimentally, 
using HUVEC cell lines, miR-210 was demonstrated to be able to stimulate the formation of 
capillary-like structure, targeting the receptor tyrosine kinase ligand ephrin-A3 (EFNA3), as well as, 
to increase the VEGF-induced cell migration. Thus, miR-210, the master miRNA of hypoxia, is able 
to enhance VEGF and vascular endothelial growth factor receptor-2 (VEGFR2) expression and 
thereby to promote angiogenesis. The up-regulation of other two miRNAs, miR-20a and miR-20b, 
seems to have direct effect on VEGF levels, but these results need to be further confirmed [Hua Z 
et al. 2006; Lei Z et al. 2009]. Moreover, in breast cancer patients, high levels of miR-210 were 
found associated with VEGF expression, hypoxia and angiogenesis [Foekens JA et al. 2008]. 
Since angiogenesis plays an essential role in tumor development, it is critical to understand the 
role of miRNAs in governing this process during hypoxia. However, despite in recent years 
numerous studies have contributed to better elucidate the mechanisms of action of these HRMs, 
future studies will be essential to verify these functions in vivo. Moreover, since hypoxia has been 
reported to be correlated with chemoresistance, HRMs may potentially become interesting 
biomarkers and therapeutic targets for anticancer therapy. 
 
1.2.9 Long non-coding RNAs 
In the last five years, lncRNA received a widespread attention as a potentially new layer of 
biological regulation. Estimates of the lncRNA gene content in the human genome ranges from 
~7,000 - 23,000 unique lncRNAs, exceeding that of protein-coding genes, ranging from 10,000 to 
20,000 [Gibb EA et al. 2011]. Despite these large numbers, only few lncRNAs have been 
characterized. LncRNAs are poorly conserved and, typically, they are long > 200bp, up to 100kb 
[Cheetham SW et al. 2013]. One of the first evidence of lncRNAs was the discovery of H19 and 
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Xist, responsible for the inactivation of one of the two X chromosome in placental female, through 
DNA methylation. Most recently, the GENCODE annotation group has produced the most 
comprehensive, high quality human lncRNA annotation to date.  
Recent transcriptomic studies in mammals have revealed an abundance of lncRNAs that lie 
interspersed with coding genes in complex ways. According to their genomic organization relative 
to protein-coding transcripts, they can be classified as overlapping transcripts (sense or antisense, 
promoter-/intronic-/3’ UTR-associated), intergenic transcripts (lincRNAs, gene-desert regions), and 
divergent transcripts (sharing same promoter with coding gene, but antisense) [Ponting CP et al. 
2009]. 
 
1.2.10 LncRNA biogenesis and function 
LncRNA transcripts, typically, have mRNA-like characteristics. They are frequently transcribed by 
RNA polymerase II, often are capped and polyadenylated, and show complex alternative splicing, 
but they apparently lack of protein-coding capacity [Cheetham SW et al. 2013]. They do not 
contain open reading frame (ORF) and are able to code for small peptides (<100 amino acids), 
whose biological significance is not completely understood. LncRNAs are an heterogeneous group 
of RNA molecules and, therefore, they are now emerging as widespread regulators of numerous 
cell physiology processes. LncRNAs have been found involved in regulating imprinting, dosage 
compensation, chromatin state, cell cycle regulation, cell-cell signaling, pluripotency, 
retrotransposon silencing, meiotic entry, recombination, telomere length, and many other functions. 
They can act immediately after transcription, both in the nucleus and in the cytoplasm, and can 
regulate gene expression, positively or negatively, at numerous levels by a variety of mechanisms. 
In particular, they can be involved in transcriptional and post-transcriptional regulation, post-
translational regulation of protein activity and organization of protein complexes. LncRNAs are 
biochemically versatile polymers. They are able to interact with sequence-specific nucleic acids, as 
RNA and DNA, and to fold into complex three-dimensional structures able to bind various ligands, 
including small molecules and peptides [Geisler S and Coller J 2013]. In particular, regarding 
interaction with proteins, lncRNAs can serve i) as decoys, precluding the access of regulatory 
proteins to DNA, ii) as scaffold, bringing two or more proteins into discrete complexes, and iii) 
guides, addressing specific protein complexes to proper localization. Moreover, lncRNA transcripts 
may act as cis and trans-acting modulators, influencing the expression of protein-coding genes in 
their immediate genomic neighborhood, or on distantly located genes. In addition, in the cytosol, 
they can act as “miRNA sponge” and sequester miRNAs to inactivate the negative regulation 
against their target genes. Regarding gene expression regulation, one of the most important 
mechanism is the chromatin modification. LncRNAs such as HOTAIR (HOX transcript antisense 
RNA) or Xist (X-inactive-specific transcripts) have been found associated with the proteins of the 
histone-modifying complex, as PRC2 (Polycomb repressive complex 2) and LSD1 (Ly-specific 
demethylase 1), inducing heterochromatin formation in specific genomic loci, and leading to reduce 
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target gene expression. In this way, HOTAIR and other lncRNAs function as scaffolds, coordinating 
the interaction and the localization of different proteins and forming cellular substructures and 
protein complexes [Gutschner T and Diederichs S 2012] . 
 
1.2.11 LncRNAs in cancer 
Several recent studies suggest that lncRNAs may have important roles in disease, most notably in 
oncogenesis. In Table 1.2 the majority of lncRNAs discovered so far and involved in different types 
of cancer are summarized [Gutschner T and Diederichs S 2012]. LncRNAs may, for example, 
confer to cancer cells the ability to evade growth suppression. For instance, the long intergenic 
ncRNA p21 (lincRNA-p21), located in the proximity of the cell cycle regulator gene Cdkn1a, was 
reported as a direct p53 target, in response to DNA damage. In normal cells, lincRNA-p21 
mediates the binding of hnRNP-k (an RNA binding protein) to its genomic targets, which finally 
leads to gene silencing and induction of apoptosis. In cancer, lincRNA-p21 acts as an inhibitor of 
the p53-dependent transcriptional pathway, particularly as a transcriptional repressor on gene 
regulating apoptosis [Huarte M et al. 2010]. Ji et al identified Metastasis-associated Lung 
Adenocarcinoma Transcript 1 (MALAT-1), as a prognostic marker for metastasis and patient 
survival in non-small cell lung cancer (NSCLC). This lncRNA promotes the cell ability to invade and 
form distant metastases. MALAT-1 transcript regulates alternative splicing of pre-mRNAs by 
modulating the levels of active serine/arginine (SR) splicing factors. In particular, it was found to 
affect the transcriptional and post-transcriptional regulation of cytoskeletal and extracellular matrix 
genes [Ji P et al. 2003]. This transcript is highly conserved across species and it is widely 
expressed in many human tissues, and up-regulated in various cancer types, as breast, prostate, 
colon, liver and uterus. Particularly, its overexpression has been linked to an increase in cell 
proliferation and migration, in lung and colorectal cancer cells [Hauptman N and Glavac D 2013].  
More interestingly, lncRNAs have been found implicated in angiogenic process. A natural 
antisense transcript (NAT), complementary to the 3’ untranslated region of the hypoxia inducible 
factor-1α (HIF-1α), called αHIF, negatively regulates the expression of HIF-1α, an important 
regulator of angiogenesis. Overexpression of αHIF triggers HIF1α mRNA decay and HIF1α and 
αHIF constitute a negative feedback loop [Rossignol F et al. 2002]. LncRNA αHIF has been found 
in several cancers and, in particular, its overexpression has been associated with worst prognosis 
in breast cancer [Cayre A et al. 2003]. Regarding, the Cancer Hallmark “resisting cell death”, 
PANDA (p21 associated ncRNA DNA damage activated) limits the expression of pro-apoptotic 
genes, such as FAS and BIK, by acting in trans as a decoy for the transcription factor NF-YA 
[Hung T et al. 2011]. These described lncRNAs are directly implicated in cancer initiation, 
progression and metastasis, and may become important diagnostic markers or therapeutic targets 
in the treatment of cancer. Moreover, many lncRNAs are expressed in a tissue- and cancer-type 
restricted manner and have already shown to be useful as prognostic markers (e.g HOTAIR in 
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breast cancer patients or MALAT-1 in early stage lung adenocarcinoma) [Gupta RA et al. 2010; Ji 
P et al. 2003]. 
 
Table 1.2: LncRNAs involved in cancer mechanisms 
    
 
1.2.12 LncRNAs in HGSOC 
Recently (2013) Akrami et al performed a large-scale genomic analysis of lncRNAs in HGSOC, 
based on TGCA molecular dataset generated on a total of 407 advance stage HGSOC tumor 
biopsies [Akrami R et al. 2013]. To investigate the global copy-number alterations and lncRNA 
expression across samples, they based the analyses on the comprehensive GENCODE lncRNA 
catalog. Analyzing data from deep coverage RNA sequencing and DNA copy-number arrays, they 
identified simultaneous copy-number profiles and expression data for 10,419 lncRNA genes. They 
described global association between DNA copy-number and lncRNA expression, and identified 
lncRNA signatures associated with the four robust subtypes of HGSOC (immunoreactive, 
differentiated, proliferative, and mesenchymal), based on their gene expression profiles. In 
particular, by examining region of focal copy number alteration, they discovered on a subset of 
tumors, an intergenic region, termed AXI region, between the ACBD6 and XPR1 genes, on 
chromosome 1. This region, characterized by focal somatic amplification, lacks of protein-coding 
genes, but contains a single annotated lncRNA gene, called OVAL (ovarian adenocarcinoma 
amplified lncRNA). Moreover, they screened other 16 TGCA cancer types, and, interestingly, they 
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reported OVAL locus focal amplification also in serous endometrial carcinoma, a disease sharing 
several clinical and molecular similarity with HGSOC. 
Although focal amplification of the AXI region was found only in the 3.9% of HGSOC samples 
analyzed, the frequency is comparable to other somatic mutations, such as BRCA1 and BRCA2 
(3.5% and 3.2%, respectively). It has been hypothesized that OVAL may exert its functions 
predominantly at cytoplasm level, and independently from the nearest protein-coding neighbors, 
but further experiments are needed to better understand its role in tumor development. 
More recently, another group of research focused the attention on the analysis of HGSOC 
transcriptome [Barrett CL et al. 2015]. They developed and deeply evaluated a systematic process 
to identify mRNA isoforms with tumor-specific expression in HGSOC. Interestingly, as researchers 
premised in the paper, commonly the mRNA expression is defined tumor-associated, regarding the 
level of expression (up and down-regulated), compared to normal tissue. Notably, they focused the 
study on the selection of “tumor-specific” mRNA isoforms, arisen for example from fusion-
transcripts, the existence of which is unknown. For the discovery of HGSOC-specific isoforms, they 
processed a large amounts of RNA-seq data of 296 HGSOC samples and 1839 normal tissues, 
obtained from TCGA and Genotype-Tissue Expression (GTEx) program, respectively. Applying 
their custom bioinformatic algorithms, they produced a list of 671 mRNA isoforms, rank-prioritized 
by likelihood of being tumor-specific. Initially, these selected isoforms  were measured by RT-
qPCR on pools of four different tumor samples and four different normal RNA samples, to filter out 
isoforms that were not expressed in tumors and/or were expressed in normal tissue. After this 
selection, only 86 isoforms were detected in the tumor pool. Then, the expression of selected 86 
isoforms were measured in an expanded set of individuals, for a total of 12 tumor samples and 18 
normal tissue samples, by RT-qPCR. Finally, a total of 33 tumor-specific or normal-restricted 
isoforms were identified and these isoforms represented 5% of the original 671 selected by RNA-
seq analysis. These isoforms are variants of genes related to oncogenesis, known to maintain the 
malignant state, as the transcription factors FOXM1 and ETV4, and that have a direct role in 
driving aggressive tumor initiating cell behavior, or are necessary for maintaining a stem-cell 
phenotype. Moreover, 15 mRNA isoforms were not expressed in the ovary or fallopian tubes, and 
so they have the tumor specificity required for an early specific detection of ovarian cancers. 
Additionally, 5 mRNA isoforms contain a unique exon that confers upon the protein a unique 
primary structure, as parathyroid hormone receptor 2 gene (PTH2R) and CD9 isoforms, making 
them interesting candidate for specific antibody targeting.  
The systematic processes, that Barrett et al developed for the discovery of tumor-specific mRNA 
isoforms, is readily and  rapidly applicable to any of the 30 or more tumor types for which sufficient 
amounts or RNA-seq data already exist. 
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2. AIMS OF THE STUDY 
High-grade serous ovarian carcinoma (HGSOC) is the most lethal gynecologic malignancy, mainly 
because the disease is frequently diagnosed at an advanced stage and it is characterized by the 
early onset of chemoresistant recurrences. The lack of reliable diagnostic and prognostic markers, 
together with the lack of effective therapies, are the major obstacles to the clinical management of 
patients with HGSOC. A new class of non-coding RNAs (ncRNAs), such as microRNA (miRNA) 
and long non-coding RNA (lncRNA), with a function of gene expression regulation, have been 
discovered to play an important role in human cancers. Increasing evidences suggest that ncRNAs 
are involved in cancer progression and development of chemoresistance, and support their role as 
potential diagnostic, predictive and prognostic biomarkers. The hypoxic condition within the tumor 
microenvironment, improving the tumor neovascularization, represents an essential event  
contributing to the development of a more aggressive HGSOC phenotype. Recently, a group of 
miRNAs, termed hypoxia regulated-miRNAs (HRMs), have been identified as key elements in 
response to hypoxia, regulating important mechanisms involved in tumor progression. The 
complexity of hypoxia molecular mechanisms has not been fully elucidated yet in HGSOC, 
therefore there is an urgent need to discover novel biomarkers clinically useful to select patients 
with hypoxic tumor, that may benefit of tailored treatments. 
Starting from these premises, the study of my PhD project aims at elucidating the transcriptional 
and post-transcriptional signatures that characterize HGSOC, both at the serum and tissue levels.  
In detail, the research effort includes: 
i) The investigation of circulating miRNAs as novel potential biomarkers for HGSOC detection; 
ii) The analysis of mRNA, miRNA and lncRNA expression profiles of HGSOC and normal tissues; 
iii) The evaluation of hypoxia-regulated miRNA expression in HGSOC and normal tissues. 
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3. MATERIALS AND METHODS 
3.1 Patient cohort 
All patients enrolled in the study were diagnosed with high grade serous ovarian carcinoma 
(HGSOC), III-IV FIGO stage and underwent a radical surgical tumor debulking with a complete 
staging procedure, followed by platinum-based chemotherapy. No patients received chemotherapy 
before surgery. Healthy donors included in the study underwent hysterectomy and bilateral 
salpingo-oophorectomy for pelvic organ prolapse or benign pathologies. Patients with a past or 
concomitant history of malignancy were excluded from the study. Clinical and anatomo-pathologic 
patients’ informations were registered and follow-up data were obtained from periodic gynecologic 
and oncological check-ups. All patients were followed from the date of surgery until death or for at 
least two years. Study approval was acquired from the institutional review board, and all patients 
signed an informed consent, according to institutional guidelines. 
 
3.1.1 Serum sample collection  
A retrospective cohort of 233 serum samples was gathered together from two independent Italian 
serum collections and divided into a training set and a validation set. The training set consists of 
serum samples from 110 patients with HGSOC III-IV FIGO stage and 52 age-matched donors, 
proven to be free of any gynecological disease, were collected at the Division of Obstetrics & 
Gynecology, ASST Spedali Civili, University of Brescia (Brescia, Italy), between 2003 and 2013. 
The validation set consisted of an independent cohort of 58 serum specimens belonging to patients 
with HGSOC and 16 serum samples from healthy donors, collected at the Division of Gynecologic 
Oncology, Gemelli Hospital, Catholic University (Rome, Italy), between 2009 and 2013.  
The two independent cohorts included in the study showed similar clinicopathologic characteristic 
distribution and are summarized in Table 3.1. 
To obtain serum samples, 7.5 ml of blood were collected in S-Monovette with clot activator 
(Sarstedt AG & Co., Nümbrecht, Germany) and centrifuged after half an hour at 3000 rpm for 10 
minutes at room temperature. The serum was then aliquoted and stored at -80°C within an hour. 
Free haemoglobin concentration was analyzed using miR-451a and miR-23a-3p expression ratio 
to exclude hemolysed samples from downstream analyses [Langhe R et al. 2015]. In the following 
Figure 3.1, the levels of the ratios across samples are represented. All samples showed a very 
homogeneous level of expression ratio, markedly below level 5, demonstrating the absence of 
hemolysis in our samples.  
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Figure 3.1. log ratio between miR-23a-3p and miR-451a expression across all samples using 
microarray technology. The dashed red line is referred to the level of 5. 
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Table 3.1. Clinicopathological features of HGSOC patients and healthy donors used in serum 
miRNA analysis 
 
 
3.1.2 Tissue sample collection 
A total of 99 snap-frozen HGSOC biopsies were obtained from the Division of Obstetrics & 
Gynecology, ASST Spedali Civili, Univ. of Brescia, between 2003 and 2013. For a total of 76 out of 
99 patients, matched serum and tumor tissue were collected.  
On the basis of chemotherapy status, patients were classified in four groups: 
· Platinum-sensitive patients, relapsing long after chemotherapy (>12 months), that could 
be re-challenged with platinum-chemotherapy, generally obtaining response.  
· Platinum partially-sensitive patients, experiencing relapse within 6-12 months from the 
last round of chemotherapy. They were generally treated again with platinum-
chemotherapy, although a less response rate is observed.  
· Platinum-resistant patients, experiencing relapse within 6 months from the end of 
therapy, were not treatable again with platinum-chemotherapy. This last group also 
includes a small fraction of platinum-refractory patients, who did not respond to 
Clinicopathological 
characteristics 
Training  cohort Validation cohort 
HGSOC 
patients 
(n=110) 
Healthy 
donors 
(n=52) 
HGSOC 
patients 
(n=58) 
Healthy 
donors 
(n=13) 
Median age (range), years 61 (36-85) 61 (38-73) 57 (34-76) 52 (26-67) 
 
Menopausal status 
 
Pre 24 (22%) - 16 (27%) - 
Post 85 (77%) - 41 (71%) - 
Missing 1 (1%) - 1 (2%) - 
 
FIGO Stage 
 
III 78 (71%) - 55 (95%) - 
IV 32 (29%) - 3 (5%) - 
 
Level of CA-125 
(UI/mL) 
 
˃ 943 52 (47.5%) - 29 (50%) - 
< 943 52 (47.5%) - 28 (48%) - 
Missing 6 (5%) - 1 (2%) - 
 
Presence of ascites 
 
Yes 90 (82%) - 31 (54%) - 
No 19 (17%) - 3 (5%) - 
Missing 1 (1%) - 24 (41%) - 
 
Lymphnode 
metastasis 
 
 
Yes 43 (39 %) - 21 (36%) - 
No 21 (19%) - 36 (62%) - 
Missing 46 (42%) - 1 (2%) - 
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platinum-therapy and experienced tumor progression during the course of 
chemotherapy.   
Patients without information about platinum-status represented Missing/Too early group.  
In particular, to define the response to chemotherapy, two endpoints were evaluated. Progression 
free survival (PFS) was considered as the time interval from diagnosis to the first appearance of 
disease progression after treatment and overall survival (OS) was represented as the time interval 
from diagnosis to the date of death due to cancer, or the last observation.  
Neoplastic tissue specimens were sharp-dissected and frozen in liquid nitrogen within 30 minutes 
of debulking surgery. For each sample, a specular hematoxylin-eosin section was reviewed by a 
staff pathologist to check for epithelial purity and only samples containing at least 70% tumor 
epithelial cells were used for the following RNA extraction. 
Normal ovarian and fallopian tube epithelial cells were obtained from a total of 30 age-matched 
patients at the Division of Obstetrics & Gynecology,  ASST Spedali Civili, Univ. of Brescia, between 
2011 to 2013.  
Normal luminal fallopian tube epithelial cells and normal ovarian surface epithelial (HOSE) cells 
were collected by scraping in 1 ml of physiological saline solution immediately after surgery and 
centrifuged at 1000 rpm for 10 minutes. The cell pellet was then resuspended in 200 μl of TRIzol 
Reagent (Life Technologies, Carlsbad, CA, USA) and stored at -80°C. All the normal samples were 
verified to be free of any neoplastic pathology before using for total RNA extraction. 
Patients clinical and pathologic characteristics are described in Table 3.2. 
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Table 3.2. Clinicopathological features of HGSOC patients and healthy donors used in tissue gene 
and miRNA analysis 
Clinicopathological 
characteristics 
HGSOC 
patients 
(n=99) 
Healthy donors 
(n=30) 
HOSEs 
(10 pools from 
15 donors) 
Fallopian Tubes 
(n=15) 
Medianage (range), years 63 (36-85) 52 (43-65) 
 
Menopausal status 
 
Pre 21 (21%) - 
Post 78 (79%) - 
Missing 0 - 
FIGO Stage 
III 73 (74%) - 
IV 26 (26%) - 
Tumor Residual 
TR=0 21 (21%) - 
TR>0 78 (79%) - 
 
Level of CA-125 
(UI/mL) 
≥ 923 46 (46.5%) - 
< 923 47 (47.5%) - 
Missing 6 (6%) - 
 
Presence of ascites 
 
Yes 85 (86%) - 
No 13 (13%) - 
Missing 1(1%) - 
Positive neoplastic 
cytology  
Yes 88 (89%) - 
No 7 (7%) - 
Missing 4 (4%) - 
 
Lymph node metastasis 
 
Yes 37 (37%) - 
No 16 (16%) - 
Missing 46 (47%) - 
Response to platinum-
based therapy 
Resistant 40 (41%) - 
Sensitive 36 (36%) - 
Partially 
sensitive 21 (21%) - 
Missing 2 (2%) - 
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3.2 Total RNA extraction 
Total RNA including miRNAs was extracted from 200 µl of serum using miRNeasy Mini kit (Qiagen, 
Milan Italy). In particular, serum samples were thawed in ice, then 1 ml of QIAzol Lysis Reagent 
(Qiagen) was added to the samples and they were kept at room temperature for 5 minutes. Ten 
synthetic spike-in RNA oligos, without sequence homology to known human miRNAs, were added 
to samples to control for variations during the preparation of total RNA and subsequent steps. RNA 
oligo sequences are displayed in Table 3.3. The spike-in RNA oligos were introduced in serum 
samples as a mixture of 12.5 fmol in a total volume of 2.5 µl. All the last steps of purification were 
performed following the manufacturer’s instructions. RNA was eluted from spin columns in 35 µl of 
nuclease-free water and 15 μl were used for miRNA expression profiling. 
Total RNA from tissue samples (included messenger RNA, microRNA and long non-coding RNA) 
was isolated using TRIZOL reagent (Life Technologies) and further purified using RNeasy 
MiniElute Cleanup kit (Qiagen), with a modified protocol for co-purification of small RNAs according 
to the manufacturer’s instructions. RNA concentration and 260/280 absorbance ratio (A260/280) 
were measured with Infinite M200 spectrophotometer (TECAN). RNA integrity was assessed with 
RNA 6000 Nano LabChip kit using the Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, 
CA, USA). RNA integrity number (RIN), generated  with Agilent 2100 Expert software, was superior 
to 8 for all RNA samples. Only samples with good RNA yield and no RNA degradation were 
retained for further experiments. RNA samples were diluted at 75 ng/μl and 50 ng/μl for gene 
expression and miRNA expression profiling, respectively. 
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Table 3.3.  Ten synthetic spike-in RNA oligo sequences 
 
Species RNA Oligo Sequence 
Kaposi sarcoma 
associated 
herpesvirus 
kshv-miR-K12-2 5’-rGrUrC rCrGrGrGrUrCrGrArU rCrUrG-3’ 
Human 
Citomegalovirus 
hcmv-miR-UL112 5’-rCrGrG rUrGrArGrArUrCrCrArGrGrC rU-3’ 
Epstein-Barr virus ebv-miR-BART8 5’-rCrGrG rUrUrUrCrCrUrArGrArUrUrGrUrArC rArG-3’ 
C.elegans cel-miR-39-5p 5’-AGCUGAUUUCGUCUUGGUAAUA-3’ 
C.elegans cel-miR-54-5p 5’-AGGAUAUGAGACGACGAGAACA-3’ 
C.elegans cel-miR-238-3p 5’-UUUGUACUCCGAUGCCAUUCAGA-3’ 
Arabidopsis  
thaliana 
ath-miR-160a 5’-UGCCUGGCUCCCUGUAUGCCA-3’ 
Arabidopsis 
thaliana 
ath-miR-171b 5’-UUGAGCCGUGCCAAUAUCACG-3’ 
Arabidopsis  
thaliana 
ath-miR-416 5’-GGUUCGUACGUACACUGUUCA-3’ 
arabidopsis 
thaliana 
ath-miR771 5’-UGAGCCUCUGUGGUAGCCCUCA-3’ 
 
 
3.3 miRNA expression profiling by microarray 
Two independent miRNA microarray profiling evaluations of serum and tissue samples were 
performed. In tissue miRNA arrays, 99 HGSOC tissues, 5 pools of HOSEs obtained from 17 
women and 11 normal luminal fallopian tube epithelia were hybridized. In serum miRNA arrays, 
110 sera from HGSOC patients and 19 sera from healthy controls were evaluated for miRNA 
expression profiling. Briefly, for tissue miRNA profiling, 100 ng of RNA, enriched in miRNA fraction, 
were Cyanine 3-pCp labeled and hybridized on the commercially available G4871A human miRNA 
Microarray, using a miRNA labeling and hybridization kit according to the manufacturer’s 
instructions (Agilent Technologies). For the analysis of circulating miRNAs, we used the 
commercially available G4872A-046064 human miRNA Microarray (Agilent Technologies), 
customized with probes for the detection of specific RNA spike-in oligos. For circulating miRNA 
profile, we hybridized fixed volume of eluted total RNA, derived from fixed serum volumes, for all 
samples tested. The arrays were washed and scanned with a laser confocal scanner (G2565BA, 
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Agilent Technologies) according to the manufacturer’s instructions. miRNA microarrays underwent 
standard post hybridization processing and the intensities of fluorescence were calculated by 
Feature Extraction software version 11 (Agilent Technologies).  
Serum raw microarray data comprised 1361 miRNAs (included Agilent quality controls and spike-in 
oligos). After a filtering step based on Agilent quality controls (see Supplementary Material for 
details), 648 miRNAs (including the 10 spike-in) were retained for further analysis. The distributions 
of the raw expression values are reported in Supplementary Figure S1. Given the small amount of 
miRNAs in serum, normalization of circulating miRNA microarray data is a challenging task. Thus, 
different normalization strategies have been tested and compared. We chose the normalization 
resulting in the more invariant spike-in oligo expression distribution across samples (see 
Supplementary Materials for details). In our data the best normalization resulted to be the cyclic 
lowess [Bolstad BM et al. 2003], in which the 10 spike-in oligos and a set of 10 invariant low 
expressed miRNAs were used as references (Supplementary Figure S1 and S2). Empirical Bayes 
test (as implemented in limma Bioconductor package) has been used to identify differentially 
expressed miRNAs between patients and healthy controls with an FDR<0.05. Hierarchical 
clustering has been performed with Euclidean distance and complete linkage.  
Tissue raw microarray data comprised 2017 microRNAs. A filter has been applied to select those 
miRNAs with reliable expression values across arrays. Specifically, we selected only miRNAs with 
at least 75% of good quality measures (as gIsPosAndSignificant Agilent flag) across samples. After 
these filtering steps, we remained with 363 miRNAs. The small amount of missing values still 
present after the filtering step was imputed with k-nearest neighbourhood method. Classic cyclic 
lowess normalization, as implemented in limmaBioC package, was applied. Empirical Bayes test 
(as implemented in limma R package) has been applied to identify differentially expressed miRNAs 
between HGSOC and normal tissues (data not shown). FDR was set to 0.05. 
The present study was carried out following REMARK guidelines [McShane LM et al. 2005]. 
 
3.4 Gene expression profiling by microarray 
One hundred and fifty nanograms of total RNA from 99 HGSOC, 6 pools of HOSEs obtained from 
19 women and 10 luminal fallopian tube epithelia were Cyanine 3-CTP labeled and hybridized with 
a One-Color Microarray-Based gene expression analysis (Low input quick amp labeling) protocol, 
according to the manufacturer’s instructions (Agilent Technologies). Commercially available 
G4851AB SurePrint G3 Human Gene Expression 8x60K v2 Microarray (Agilent Technologies) was 
used. It consists of 60K features printed in an 8-plex format (8×60 array), and can detect human 
known 27.958 genes/transcripts and 7.419 lncRNAs sourced from different public database. The 
arrays were washed and scanned with a laser confocal scanner (G2565BA, Agilent Technologies) 
according to the manufacturer’s instructions. mRNA microarrays underwent standard post-
hybridization processing and the intensities of ﬂuorescence were calculated by Feature Extraction 
(FE) software version 11 (Agilent Technologies).  
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Expression matrix was obtained using gProcessedSignal. Matrix gene expression data were 
normalized with quantile [Bolstad BM et al. 2003] and the expression values of the same probes 
(ProbeUID) were averaged. Lines containing more than thirty unavailable (NA) values were 
discarderd. After normalization, identification of differentially expressed genes (DEG) was 
performed using Limma’s Empirical Bayes test [Smyth GK 2004]. Raw p-values were adjusted for 
multiple testing with Benjamini and Hochberg False Discovery Rate [Reiner A et al. 2003]. After 
analysis, genes were deemed statistically significant if their corrected p-value was equal or lower 
than 0.01. 
 
3.5 RNA sequencing 
Among the cohort of 99 HGSOC samples, we selected a total of 28 RNA samples derived from 14 
platinum-based chemotherapy resistant patients and 14 platinum-based chemotherapy sensitive 
patients. This group of 28 total RNA samples, together with 10 control tissues, derived from 3 
HOSEs (pooled from 10 HOSEs of healthy donors) and 7 normal fallopian tubes were deep 
sequenced for the discovery of novel HGSOC specific transcripts.  
The RNA sequencing was performed by Personal Genomics, a Spin-Off of the University of Verona 
operating within the Center of the Functional Genomics of University of Verona. The sequencing 
was carried out on the Illumina HiSeq1000 platform, using the standard sequencing kit TruSeq 
Stranded Total RNA LTwithRibo-Zero TM Gold, generating 2x100 bp paired end lane. 
The high-throughput RNA-seq data alignment was performed using the Spliced Transcripts 
Alignment to a Reference (STAR) software [Dobin A et al. 2013]. STAR software was implemented 
with a strategy, called 2-pass STAR, known to be more reliable for discovery analysis [Engström 
PG et al 2013]. 
 
3.6 Serum samples: cDNA synthesis and RT-qPCR/ddPCR 
RNA from 233 serum samples (training and validation cohorts) was reverse transcribed into cDNA, 
starting from 5 µl of RNA, according to the miScript Reverse Transcription protocol (Qiagen). A 
fixed volume of eluted RNA sample was used as input for RT-qPCR, rather than a fixed quantity of 
input RNA, as previously reported [Kroh EM et al. 2010]. Two microliter of cDNA were used for RT-
qPCR experiments in triplicate using Rotor-Gene Thermal Cycler (Qiagen). Experiments were run 
in triplicate and plates were prepared by automatic liquid handling station on a final volume of 10 µl 
(QiaAgility). As there are no established endogenous miRNAs acting as normalizers for serum 
miRNA relative quantification, RT-qPCR analysis was performed on raw cycle thresholds (Cq). 
The choice of using ddPCR, a recent technique optimized for the absolute quantification of 
circulating nucleic acids, combined with Exiqon chemistry, is based on their reported optimal 
precision, reproducibility and specificity [Mestdagh P et al. 2014]. Experimentally, 3 µl of RNA 
isolated from 168 serum samples (training cohort) were reverse-transcribed in a final reaction 
volume of 20 µl, with 5X reaction buffer and 1 µl of Enzyme Mix, as reagents (miRCURY locked-
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nucleic-acid™ (LNA) Universal RT microRNA PCR system, Exiqon). According to the 
manufacturer’s protocol, a poly-A tail was added to the RNA template and cDNA was synthesized 
using a poly-T primer with a 3’ degenerate anchor and a 5’ universal tag and incubating the 
reaction at 42°C for 60 min, heat-inactivating at 95°C for 5 minutes, then immediately cooling at 
4°C. All cDNA samples were diluted 50-fold with nuclease-free water. Amplification mixture (20 µl) 
containing 10 µl 2X EvaGreensupermix (Bio-Rad), 8 µl diluted cDNA and 1 µl of miRCURY LNA 
PCR primer sets specific for hsa-miR-1246 (ID 205630,Exiqon). An absolute quantification of 
circulating miRNAs was performed with QX200 Droplet Digital PCR System (Bio-Rad). Briefly, 
each EvaGreen amplification mixture (20 µl) was mixed with 70 µl of droplet generator oil and 
loaded into the QX200 droplet generator, thus portioning each sample into 20,000 nanoliter-sized 
droplets. Emulsified samples were then transferred into a 96-well PCR plate to perform PCR to end 
point, using a conventional thermal cycle. The cycling steps were set as follow:  95°C for 5 min, 
(95°C for 30, 58°C for 1 min) x 40 cycles, 4°C for 5 min, 90°C for 5 min and infinite 4°C holding. 
The PCR plate was then loaded into the QX200 droplet reader for sample automated analysis. A 
no template control (no cDNA in PCR) and a negative control for each reverse transcription 
reaction (RT-neg) were included in every assay run for each miRNA. 
 
3.7 Tissue samples: cDNA synthesis and RT-qPCR 
Ten ng of total RNA, extracted from 99 HGSOC tissues and 25 normal tissues, were 
retrotranscribed in cDNA, according to miRCURY LNA™ Universal RT microRNA PCR system 
protocol (Exiqon), as described above. All cDNA templates were stored at -20°C and diluted 80-
fold immediately before being amplified using CFX96 Touch™ Real-Time PCR Detection System 
(Biorad). The PCR reaction (10 µl) consisted of 5 µl PCR Master Mix  (Exiqon), 1 µl sncRNA-
specific forward and reverse primer Mix  (Exiqon) and 4 µl of diluted template cDNA. PCR cycling 
steps were set as follow:  95°C for 10 min, (95°C for 10 sec and  60°C for 1 min, ramp-rate 1.6 
°C/s) x 40 cycles and infinite 4°C holding. Each real-time qPCR amplifications were followed by 
melting curve analysis. Both PCR primers (forward and reverse) are optimized with LNA™, 
resulting in high sensitivity, as well as exceptional specificity, of the assays that allow 
discrimination between closely related microRNA sequences. Assays evaluated in our study meet 
the quality criteria set by Exiqon, with an amplification efficiency over than 85%. All reactions were 
run in triplicate and no template controls (no cDNA in PCR) were included in each assay run for 
each primer set. We included a minus-reverse transcriptase ("-RT") controls in real-time qPCR 
experiments for each sample and each sncRNA. An inter-run calibration sample was used in all 
plates to correct for the technical variance between the different runs and to compare results from 
different plates. Cq determination was performed with CFX Manager Software (Bio-Rad 
Laboratories) using the single threshold mode. 
 
 
39 
 
3.8 Statistical analysis 
miRNA and gene microarray data analysis were described in paragraph 3.3 and 3.4, respectively. 
RNA sequencing analysis were reported in paragraph 3.5. 
A supervised pathway analysis between different groups (platinum-resistant vs platinum-sensitive 
and partially sensitive patients) was performed. “Graphite web” is a novel tool recently developed 
by a group of statisticians of University of Padova (Padova, Italy) for topological-based pathway 
analysis, based on high-throughput gene expression data analyses [Sales G et al. 2013]. It was 
used for pathway analyses and network visualization for gene expression data. It combines 
topological and multivariate pathway analyses with an efficient and interactive system of network 
visualizations, using Clipper method. Clipper is a two-step empirical approach based on Gaussian 
graphical models, which identifies pathways with means or covariance matrices significantly 
different between experimental conditions. It also selects the portions of the pathway, called signal 
paths, which are associated the most with the given phenotype. AlphaMean represents an 
adjusted p-values of CliPPER test on the means of the pathways between groups. 
For miRNA expression experiments, median values were compared using the non-parametric 
Mann-Whitney t-test. Differences were considered statistically significant with a two sided p-value 
less than 0.05. Survival curves were plotted using the Kaplan-Meier method, and differences were 
tested using the log-rank test. For survival analysis two end-points (cancer progression and death 
due to cancer) were used to calculate progression-free survival (PFS) and overall survival (OS), 
respectively. For all two end-points the last date of follow-up was used for censored subjects. 
Survival models were fitted using the Cox proportional hazard regression models. Linear 
discriminant analysis and the receiver-operating-characteristic (ROC) curves were used to 
estimate sensitivity and specificity for each biomarker in the training and validation sets. All 
statistical analyses were performed using the R language. 
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4. RESULTS 
4.1 Circulating miRNA microarray analysis 
4.1.1 Cohort description and study design 
Sera collection was obtained from two independent cohorts of HGSOC patients (total cases, =168) 
and healthy donors (total cases, =65), with comparable distribution of clinic-pathologic 
characteristics as detailed in Table 3.1. The study was organized into two steps, namely 
“discovery” and “evaluation” phase. In the discovery phase, known miRNA species differentially 
expressed between the sera of HGSOC patients (n= 110) and healthy donors (19 out of 52) of the 
training set, were identified first by array technology and further validated by RT-qPCR. In the 
evaluation phase, the expression profile of the candidate circulating miRNAs was examined in an 
external and independent cohort of sera (from now onwards known as validation set) of HGSOC 
patients (n= 58) and healthy donors (n= 13). The median age at diagnosis was 61 and 57 years for 
the training and the validation set, respectively, with the vast majority of women in postmenopausal 
status (77% and 71% for the training and the validation set, respectively). Serum samples were 
withdrawn at diagnosis, before any treatment. All patients were staged according to FIGO 
(Federation International of Gynecology and Obstetrics) guidelines as stage III-IV [Prat J et al. 
2015], with high-grade serous histological type. The median CA125 value at diagnosis was 
943UI/ml. As shown in Table 3.1, the CA125 levels were higher than the above level in the 47% of 
patients of the training set and in the 50% of patients of the validation set. Some patients showed 
presence of ascites (82% training set and 54% validation set, respectively) and lymph node 
metastasis (39% for the training set and 36% for the validation set). miRNA landscape analysis 
was performed on the training set to discover differentially expressed known miRNAs between 
sera of healthy donors and sera of women with diagnosis of HGSOC. The validation set was used 
as a second and independent cohort of sera to support the robustness of our analysis and to 
validate miRNAs found differentially expressed in the training set.  
 
4.1.2 Discovery of candidate diagnostic miRNAs in serum by microarrays 
To identify the entire repertoire of currently known miRNAs expressed exclusively in patients with 
diagnosis of stage III-IV HGSOC, miRNA microarray experiments were performed on 110 sera of 
HGSOC patients and 19 healthy donors, enrolled in the training set. After a comparative analysis, 
we selected, as the best normalization strategy for our data, the cyclic lowess normalization with 
weights on spike-in RNA oligos and low invariant miRNAs (hereafter called CLWsim) (see 
Supplementary Materials for details). CLWsim normalization revealed a total of 97 miRNAs as 
differentially expressed between sera of HGSOC patients and healthy donors (from now on 
referred to as DEM, differentially expressed miRNA). The complete list of 97 DEM with relative log 
expression values in both healthy and ovarian cancer patients is reported in Supplementary Table 
S1. Of these, 92 miRNAs (95%) resulted up-regulated, and five (5%) resulted down-regulated in 
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the sera of patients compared to healthy donors. Similarity across samples was further 
investigated by unsupervised cluster analysis using DEM expression levels. The dendrogram 
depicted in Figure 4.1 shows a clear separation of three groups of patients (called C1, C2 and C3). 
With the exception of seven healthy patients, cluster C2 and C3 are mainly composed by HGSOC 
patients, while cluster C1 is mainly composed of healthy controls. No significant differences have 
been observed regarding the clinical characteristics of the C2 and C3 groups. 
 
 
4.1.3 Validation of candidate circulating miRNAs by RT-qPCR in the training set 
Since above analyses are based on array measures, and therefore obtained within a complex 
mixture of transcripts, orthogonal validation miRNAs by independent techniques, like RT-qPCR, 
need to be performed before any assessment of their clinical relevance. Due to the limits of PCR-
based approaches and the low abundance of miRNA species in the sera of HGSOC patients, 
validation experiments were performed on a selection of DEM according to the following criteria: i) 
highest average expression in both patients and healthy donors; ii) highest log fold change, 
measured in patients compared to healthy donors; iii) lower adjusted p-value. Then only miRNA 
expression with Ct <36 were considered reliable.  
In Table 4.1 the complete panel of the nine DEM selected for independent validation is reported 
(i.e., miR-1246, miR-595, miR-574-5p, miR-483-3p, miR-4290, miR-2278, miR-32, miR-4281, and 
miR-3148). Of these, miR-1246 and miR-574-5p resulted as DEM in matched tissue samples. To 
note, except for miR-4281, all DEM selected for further RT-qPCR validation lies in the intersection 
of the three different normalization approaches (Figure 4.2).   
RT-qPCR were performed on sera of 110 HGSOC patients and 52 healthy donors enrolled in the 
training set. Data reported  in Table 4.2 show the median CT values for miR-1246, miR-4290, miR-
595, and miR-2278 (all p-values ≤0.0002, FC=9, FC=3.2, FC=8.4, FC=3, respectively) as the most 
Figure 4.1: Heat map and cluster analysis, using all the differentially expressed miRNAs. Almost 
all healthy controls are grouped in Cluster C1. 
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significantly up-regulated miRNAs in the serum of HGSOC patients compared to healthy donors in 
the training set. miR-574-5p and miR-483-3p were not confirmed. RT-qPCR Ct values for miR-32-
3p, miR-4281 and miR-3148 resulted above the selected cut-off (i.e., Ct=36) and therefore were 
discarded from downstream validation. 
 
 
Table 4.1: Nine circulating miRNAs selected for RT-qPCR validation, based on microarray results. 
Rank 
from 1 to 97 miRNAs Adjust ρ-value 
Mean log2expression log FC 
HGSOC Control 
1 hsa-miR-483-3p 0.00001 4.45 3.42 1.03 
5 hsa-miR-4290 0.00001 4.06 3.10 0.96 
12 hsa-miR-595 0.0004 5.03 3.54 1.49 
15 hsa-miR-2278 0.0005 4.41 3.19 1.22 
18 hsa-miR-32-3p 0.0008 5.19 3.73 1.46 
24 hsa-miR-3148 0.0008 4.57 3.23 1.34 
50 hsa-miR-1246 0.0077 7.18 6.24 0.94 
64 hsa-miR-574-5p 0.0154 7.27 5.83 1.44 
73 hsa-miR-4281 0.0218 11.37 10.50 0.87 
 
Figure 4.2: Venn diagram of the list of differentially expressed miRNAs between patients and 
controls according to different normalizations. In tables are reported the number of differentially 
expressed miRNAs identified by each normalizations and the rank of the selected miRNAs in 
each list of DEM.  
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Table 4.2: Expression levels of nine selected miRNAs evaluated by RT-qPCR. 
 
 
 
 
 
RT-qPCR 
Training set   Validation set  
Control HGSOC Control HGSOC 
miR-1246 
median (CT) 
[IQR] 
26.4 
[2.13] 
23.44 
[2] 
27.39 
[0.49] 
25.75 
[1.3] 
mean (CT) 
[sd] 
25.83 
[1.33] 
23.41 
[1.6] 
27.56 
[0.62] 
25.82 
[1.15] 
p-value (2-CT) < 0.00001 <0.00001 
miR-574-5p 
median (CT) 
[IQR] 
28.12 
[1.59] 
28.24 
[2.23] 
30.35 
[1.31] 
29.58 
[1.85] 
mean (CT) 
[sd] 
28.16 
[1.38] 
28.32 
[1.66] 
30.67 
[0.97] 
29.6 
[1.24] 
p-value (2-CT) 0.6637 <0.00001 
miR-483-3p 
median (CT) 
[IQR] 
32.41 
[1.17] 
32.77 
[1.57] 
31.87 
[0.8] 
32.12 
[1.17] 
mean (CT) 
[sd] 
32.44 
[0.91] 
32.72 
[1.24] 
31.84 
[0.62] 
32.28 
[1.16] 
p-value (2-CT) 0.9799 0.4145 
miR-4290 
median (CT) 
[IQR] 
33.25 
[1.95] 
32.27 
[2.33] 
30.11 
[0.75] 
31.09 
[1.46] 
mean (CT) 
[sd] 
33.4 
[1.58] 
32.62 
[1.86] 
30.21 
[0.8] 
31.08 
[1.19] 
p-value (2-CT) 0.0002 0.0344 
miR-595 
median (CT) 
[IQR] 
34.29 
[2.01] 
33.23 
[2.55] 
34.44 
[2.03] 
32.87 
[2] 
mean (CT) 
[sd] 
34.37 
[1.76] 
33.17 
[2.39] 
34.13 
[1.28] 
32.85 
[1.76] 
p-value (2-CT) 0.0002 <0.0001 
miR-2278 
median (CT) 
[IQR] 
36.71 
[2.99] 
33.90 
[1.56] 
33,59 
[0,32] 
33,45 
[0,74] 
mean (CT) 
[sd] 
36.44 
[2.21] 
34.06 
[1.61] 
33.58 
[0.36] 
33.39 
[0.52] 
p-value (2-CT) 0.0000 0.0373 
miR-32-3p 
median (CT) 
[IQR] 
35.87 
[1.8] 
37.12 
[1.67] 
38.23 
[1.53] 
36.84 
[2] 
mean (CT) 
[sd] 
36.16 
[1.48] 
37.16 
[1.7] 
38.34 
[2.42] 
37.29 
[1.68] 
p-value (2-CT) - - 
miR-4281 
median (CT) 
[IQR] 
38.79 
[3.15] 
36.68 
[1.67] 
37.43 
[2.4] 
37.57 
[1.81] 
mean (CT) 
[sd] 
38.75 
[1.98] 
36.81 
[1.68] 
37.8 
[1.48] 
37.61 
[1.65] 
p-value (2-CT) - - 
miR-3148 
median (CT) 
[IQR] 
39.43 
[3.29] 
37.75 
[2.45] 
38.31 
[1.64] 
38.2 
[1.38] 
mean (CT) 
[sd] 
39.83 
[2.46] 
37.83 
[2.42] 
37.55 
[2.08] 
38.35 
[1.53] 
p-value (2-CT) - - 
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4.1.4 Independent evaluation of candidate circulating miRNAs in HGSOC patients 
In order to evaluate the expression levels of candidate circulating miRNAs in the sera of HGSOC 
patients, we performed RT-qPCR analysis in a second independent cohort of 58 HGSOC and 13 
healthy donors sera samples. Accordant with the results in the training set, the expression levels of 
miR-1246, miR-595 and miR-2278 displayed a significant over-expression (all p-value ≤0.03, 
FC=5, FC= 4.7, FC=0.42, respectively) in the serum of HGSOC patients compared to healthy 
donors (Table 4.2). Conversely, miR-4290 showed an opposite trend. The boxplots of RT-qPCR Ct 
values of the three candidate biomarkers in both training and validation sets are reported in Figure 
4.3. Furthermore, miR-1246 and miR-595 remained significantly up-regulated in HGSOC patients 
of both training and validation sets, using miR-15b as normalizer (Supplementary Table S2). 
Indeed, miR-15b is one of the most invariant miRNAs in our cohort of serum samples by 
microarrays, in accordance with its previously reported role as a reliable reference for circulating 
miRNA analysis in lung cancer [Bianchi F et al. 2011]. 
 
 
Figure 4.3: Boxplots of the RT-qPCR Ct values showing upregulation of the three candidate 
biomarkers in HGSOC patients compared to controls in both training and validation sets.  
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4.1.5 Evaluation of the diagnostic potential of miRNAs for HGSOC 
To assess the efficiency of above three miRNAs as diagnostic markers for HGSOC detection, we 
performed ROC curve analysis on each miRNA to estimate sensitivity and specificity. Results, 
reported in Figure 4.4 and Table 4.3 on the entire cohort of 168 HGSOC and 65 healthy donors, 
revealed that the three candidate miRNAs were of value in distinguishing HGSOC patients from 
healthy donors. For miR-1246, the sensitivity was 87%, the specificity was 77% and the accuracy 
was 84%, with an AUC of 0.89. For miR-595, the sensitivity was 47%, the specificity was 84% and 
the accuracy was 57%, with an AUC of 0.69. For miR-2278, the sensitivity was 81%, the specificity 
was 66% and the accuracy was 77%, with an AUC of 0.76. These data indicated that miR-1246, 
which showed the greatest ability in differentiating HGSOC patients from controls, could act as a 
suitable biomarker for detecting HGSOC patients. 
 
 
 
Figure 4.4: ROC curves showing the diagnostic performance of each single miRNA markers in the 
training set, in the validation set and the combination both patient’s cohorts. 
 
 
 
 
 
 
 
 
 
 
Training set  Validation set  Combined 
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Table 4.3:  Diagnostic performance of selected miRNA biomarkers in the training set, in the 
validation set and in the combination of both sets. (Sp for specificity, Se for sensitivity, Acc for 
accuracy and Th for threshold). 
ROC Index Training set  Validation set Combined 
miR-1246 
Th 24.95 26.77 0.41 
Sp 0.71 1 0.77 
Se 0.93 0.77 0.87 
Acc 0.86 0.82 0.84 
miR-595 
Th 32.47 32.65 -0.29 
Sp 0.86 1 0.84 
Se 0.44 0.48 0.47 
Acc 0.57 0.58 0.57 
miR-2278 
Th 35.38 33.13 0.26 
Sp 0.69 1 0.66 
Se 0.91 0.31 0.81 
Acc 0.84 0.44 0.77 
 
4.1.6 Absolute quantification of miR-1246 by droplet digital PCR (ddPCR) 
According to the diagnostic accuracy, the statistical significance and the average expression 
difference between cases and controls (see Figure 4.3 and 4.4), miR-1246 was the most promising 
diagnostic serum biomarker. Thus, we decided to validate its expression levels with an additional 
technique, using EvaGreen-based ddPCR technology. The quantification by ddPCR, expressed as 
copies/µl, (Figure 4.5) further confirmed the diagnostic potential of miR-1246 (p<0.0001) in 
discriminating HGSOC patients and healthy donors. 
 
       
Figure 4.5: Boxplot of the absolute quantification of miR-1246 by ddPCR in HGSOC patients 
compared to controls. Results are presented as copies per microliter of the amplification reaction 
mixture. 
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4.2 Global gene and miRNA expression profiling in HGSOC tissue samples 
4.2.1 Cohort description 
Tissue samples enrolled in the study were obtained from 99 HGSOC patients and 30 age-matched 
healthy donors. As described in Table 3.2, the median age at diagnosis was 63 and 58 years, for 
HGSOC patients and healthy donors, respectively, with the 79% of patients in postmenopausal 
status. Tissue samples were collected at the time of surgery, before any treatment. All patients 
were staged according to FIGO guidelines (Federation International of Gynecology and Obstetrics) 
as stage III-IV, with high-grade serous histological type. Women with diagnosis of HGSOC showed 
a median CA125 value >943UI/ml in 46.5%, residual tumor ˃0 in 79%, presence of ascites in 86%, 
positive neoplastic cytology in 89% and lymph node metastasis in 37% of cases. According to 
response to standard treatment, patients were classified as platinum-resistant (n=40, 41%), 
platinum-sensitive (n=36, 36%) and platinum-partially sensitive (n=21, 21%). 
 
4.2.2 Gene expression microarray analysis 
Figure 4.6 showed the heatmap of the 18.626 mRNA values obtained after pre-processing and 
data normalization. On a global scale, a large part of the entire set of genes was similar across 
samples. 
The unsupervised analysis, performed on the entire cohort of 99 HGSOC samples with their 
respective expression arrays, generated no evident clusters using all genes in the platform; this 
analysis did not help to separate patients on the basis of their response to chemotherapy. 
Figure 4.6: Cluster analysis with the whole-matrix of genes. 
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Secondly, we performed a statistical analysis to identify genes differentially expressed among 
patients grouped according to response to platinum-based therapy (see Table 3.2). Platinum-
resistant patients (group 1) were compared with platinum-sensitive (group 2)  and partially 
platinum-sensitive (group 3), but no differentially expressed genes (DEGs) were identified, with a 
FDR (false discovery rate) ≤ 0.05 (Table 4.4). On the other hand, limiting the comparison to 40 
resistant patients versus 35 sensitive patients, HOMER2 was identified as the only significant 
DEG, with a FDR<0.05 (false discovery rate). HOMER2 was able to differentiate the two groups 
and demonstrated a downregulation in the group of resistant patients (Table 4.5). 
  
Table 4.4: List of the first 10 DEGs resulted from the statistical comparison between 40 resistant 
patients and 54 sensitive plus partially sensitive ones. No gene is significantly differentially 
expressed between groups, considering the adjusted p-value. 
 
     
Table 4.5: List of the first 10 DEGs from the statistical comparison between 40 resistant patients 
and 35 sensitive ones. Only the first gene is statistically significant. 
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4.2.3 Pathway analysis 
Applying Graphite and Clipper method, we performed a pathways analysis, comparing group 1 
versus group 2 and 3. A total of 58 pathways differently expressed between groups has emerged. 
The topological pathway analysis compared 40 platinum-resistant patients with a total of 54 
platinum-sensitive plus partially-sensitive patients. In Table 4.6 were reported the first ten pathways 
of the list.  
 
Table 4.6: List of the first ten pathways significantly expressed among groups 
Pathway alphaMean alphaVar 
Amino sugar and nucleotide sugar metabolism               0.02                 0 
Dorso-ventral axis formation  0.04 0.01 
Tryptophanmetabolism 0.01 0.06 
Glioma  0.06 0.03 
Metabolism of xenobiotics by cytochrome P450  0.01 0.08 
Africantrypanosomiasis 0.07 0.03 
ErbBsignalingpathway 0.05 0.06 
RIG-I-like receptor signaling pathway  0.04 0.07 
Prostate cancer 0.07 0.05 
Hedgehogsignalingpathway 0 0.13 
 
4.2.4 Discovery of specific HGSOC tissue miRNAs by microarray 
Microarray analysis revealed 265 DEM (123 up-regulated and 142 down-regulated) in 99 HGSOC 
tissue samples compared to 16 tissues from HOSEs and fallopian tubes (data not shown). 
According to response to platinum-based chemotherapy and prognosis, we identified a total of 9 
DEM (miR-199b-5p, miR-423-5p miR-455-3p, miR-22-3p, miR-199a-3p, miR-15b-5p, miR-140-5p, 
miR-1246 miR-320c) in the group of patients platinum-resistant and partially platinum-sensitive 
compared to platinum-sensitive patients, and significantly associated with survival variables (OS 
and PFS), as reported in Table 4.7. 
 
Table 4.7: A total of 9 DEM associated with platinum-resistance and prognosis  
Tissue miRNAs Log Fold Change p-value 
OS p-value 
(median) 
PFS p-value 
(median) 
hsa-miR-199b-5p 0.847 0.002 0.002 0.001 
hsa-miR-423-5p 0.362 0.001 0.009 0.004 
hsa-miR-455-3p 0.769 0.002 0.005 0.001 
hsa-miR-22-3p 0.616 0.004 0.009 0.018 
hsa-miR-199a-3p 0.667 0.02 0.007 0.003 
hsa-miR-15b-5p -0.319 0.022 0.039 0.0001 
hsa-miR-140-5p 0.297 0.039 0.032 0.003 
hsa-miR-1246 0.482 0.042 0.008 0.017 
hsa-miR-320c 0.32 0.017 0.04 0.032 
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4.2.5 Comparison of miRNA expression between matched serum and tissue samples  
We next questioned whether or not DEM observed in the sera of HGSOC patients could reflect 
those present in the tumor masses. To that end, we compared miRNA expression in those patients 
for whom matched serum and tumor tissue were available. As described in Figure 4.7, ten miRNAs 
shared a differential expression in tissue and serum between cancer patients and normal donors. 
Of these, eight miRNAs showed the same trend of up/down regulation in cases and controls, while 
2 miRNAs display an opposite trend. 
 
              
 
Figure 4.7: Venn diagram of the list of differentially expressed miRNAs between tissue and serum 
samples. After filtering steps, we detected 638 miRNAs in sera and 363 miRNAs in tissues. Of 
these, 214 were in common. Among these 214 miRNAs, we identified 10 miRNAs differentially 
expressed in both sera and tissues, of which 8 with the same trend. 
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4.2.6 Identification and validation of candidate reference for miRNA quantification by RT-
qPCR in HGSOC tissue samples 
Since there is a lack of consensus in the literature regarding the most suitable endogenous control, 
before starting with the experiments for the validation of miRNA expression data, we decided to 
identify and validate the most stable reference sncRNAs (small non-coding RNAs) for 
normalization of miRNA RT-qPCR expression data in HGSOC. 
We selected a panel of seven potential endogenous controls derived from the literature (U6, 
SNORD48, miR-92a-3p, let-7a-5p, SNORD61, SNORD72, SNORD68), suggesting their use for 
normalization of qPCR studies in HGSOC tissue samples. Then, we added to the analysis four 
reference miRNAs, miR-103a-3p, miR-423-3p, miR-191-5p and miR-16-5p, selected and validated 
from Exiqon for normalization of miRNA expression levels in human tissue samples during real-
time PCR. This panel of eleven miRNAs was integrated with additional two miRNAs, miR-26a-5p 
and miR-1249, emerged as the most invariant by microarray analysis, performed on 99 HGSOC 
and 16 normal tissue samples (see paragraph 3.3). Quantitative real-time PCR was performed on 
a portion of the entire cohort of HGSOC (n=75) and on 25 normal tissues (n=25, including ovarian 
and tubal epithelia), to assess the expression pattern of the 13 selected reference sncRNAs. 
Stability of candidate endogenous controls was evaluated by geNorm [Vandesompele J et al. 2002] 
and NormFinder algorithms [Long JS et al. 2000] and validated with an equivalence test (Two-One-
Sided Test approach, TOST) [Wellek S 2003]. 
Combining results from the three different statistical approaches, SNORD48 emerged as stably 
and equivalently expressed between malignant and normal tissues. Among malignant samples, 
considering groups based on residual tumor, miR-191-5p was identified as the most equivalent 
sncRNA (Table 4.8). Based on these results, for the following experiments of miRNA relative 
expression quantification, we decided to use SNORD48 and miR-191-5p, as best reference 
sncRNAs within our cohort of HGSOC compared to normal tissues and within HGSOC tissues, 
respectively.   
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Table 4.8: Log Fold changes in reference sncRNA expression between HGSOC and normal 
control samples, and among patients with no residual tumor versus patients with residual tumor 
(90% confidence intervals,; p-values for linear models; * null hypothesis of no equivalence rejected; 
[εL,εU]=[-0.36,0.36]). 
 HGSOC vs Control RT=0 vs RT>0 
sncRNAs Log FC CI 90% p-value Log FC CI 90% p-value 
miR-16-5p -1.87 -2.36;-1.38 <0.001 -0.16 -0.43;0.11 0.328 
miR-191-5p -0.10 -0.44;0.24 0.625 0.06 -0.23;0.36* 0.725 
miR-423-3p 0.21 -0.18;0.59 0.375 0.60 0.04;1.15 0.087 
let-7a-5p -0.20 -0.59;0.19 0.401 0.48 -0.01;0.98 0.108 
miR-103a-3p -0.15 -0.60;0.31 0.601 0.28 -0.35;0.90 0.465 
miR-92a-3p -1.89 -2.23;-1.55 <0.001 0.40 0.005;0.80 0.096 
SNORD68 -0.23 -0.55;0.09 0.229 0.28 -0.14;0.71 0.274 
SNORD61 0.33 -0.08;0.74 0.190 -0.05 -0.42;0.32 0.828 
SNORD72 1.21 0.80;1.63 <0.001 0.25 -0.25;0.74 0.408 
SNORD48 0.02 -0.28;0.32* 0.924 0.25 -0.14;0.64 0.287 
U6 -0.53 -0.84;-0.23 0.003 0.56 0.06;1.06 0.066 
miR-26a-5p 0.57 0.34;0.80 0.013 -0.10 -0.35;0.14 0.102 
miR-1249 1.33 1.13;1.54 0.000 -0.17 -0.38;0.04 0.154 
 
 
4.2.7 miR-1246 expression validation by RT-qPCR and association with patient survival 
Since the up-regulation of circulating miR-1246 levels in HGSOC patients has been confirmed by 
three different techniques and since miR-1246 up-regulation in HGSOC biopsies was correlated 
with platinum-resistance and worst prognosis by microarray analysis, we focused on the validation 
of its expression in our cohort of tumor and normal tissues (from HOSE and fallopian tubes) by RT-
qPCR. Interestingly, by microarray analysis, miR-1246 expression emerged down-regulated in 
HGSOC tissues compared to normal controls. As represented in Figure 4.8 A, we confirmed the 
down-regulation of miR-1246 expression levels in HGSOC samples compared to HOSE, but we 
did not detect a significantly differential expression compared to fallopian tubes. This result mirrors 
the global miRNA expression trend emerged by microarray where, as revealed by principal 
component analysis (PCA) in Figure 4.9, luminal fallopian tube surface epithelium miRNA profile 
shares a higher similarity with HGSOC miRNA profile, compared to ovarian surface epithelium. 
Moreover, miR-1246 over-expression in HGSOC tissues was significantly associated with 
platinum-resistant compared to platinum-sensitive patients (p-value=0.047) (Figure 4.8), by RT-
qPCR. Kaplan-Meier survival curves showed that OS and PFS decreased in patients with high 
miR-1246 expression compared to those with low miR-1246 expression (p-value<0.001, HR=2.57;  
p-value=0.024, HR=1.68; respectively). In addition, multivariate analysis, considering miR-1246 
expression and residual tumor, revealed miR-1246 over-expression as an independent prognostic 
factor for poor OS and PFS (p-value=0.001, HR=2.42; p-value<0.05, HR=1.59; respectively). 
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Figure 4.8: A miR-1246 expression levels in HGSOC samples compared to normal controls, 
composed by HOSE and fallopian tube by RT-qPCR. B miR-1246 expression levels among 
HGSOC samples: comparison between chemo-resistant vs chemo-sensitive patients.  
p -value<0.0001 
Principal Component Analysis 1 
Figure 4.9: PCA based on the microarray expression levels of the 200 most variable miRNAs 
among 99 HGSOC, 11 fallopian tubes and 5 HOSEs (pooled from 17 healthy donors). 
A B 
p-value =0.047 
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Figure 4.10: Kaplan-Meier survival curves for overall survival (OS) and progression-free survival 
(PFS) according to tissue miR-1246 expression from 99 HGSOC patients. A The OS rate of 
HGSOC patients with high or low miR-1246 expression; B The PFS rate of HGSOC patients with 
high or low miR-1246 expression.  
 
4.2.8 Identification and validation of hypoxia-regulated miRNAs (HRMs) by RT-qPCR 
We focused our analysis on a group of 16 miRNAs (miR-210/24-3p/23a-3p/27a-3p/21-5p/23b-
3p/26b-5p/103a-3p/107/192-5p/93-5p/181b-5p/30b-5p/26a-5p/125b-5p/181a-5p) belonging to the 
group of hypoxia-regulated miRNAs (HRMs), selected from the literature and already emerged as 
relevant in other solid tumors. Most of the HRMs showed a significant differential expression in 
HGSOC compared to normal tissues, by microarray analysis (Table 4.9). Among them, miR-210, 
being the most widely studied miRNA associated with hypoxia and considered a master miRNA of 
the hypoxic response, was selected for further validations. Additionally, we validated miR-23a-3p 
and miR-27a-3p, showing a significant and a borderline significant association with poor overall 
survival, respectively (Table 4.9), and miR-24-3p located on the same miR-23a-3p/27a-3p gene 
cluster. RT-qPCR, using SNORD48 as reliable reference within HGSOC tissue samples and 
controls, confirmed the over-expression of all the four HRMs tested in HGSOC compared to normal 
tissues, as reported in Figure 4.11 (all p-values≤ 0.002). Moreover, we confirmed the significant 
over-expression of miR-23a-3p in the group of patients resistant compared to platinum-sensitive 
patients (p-value=0.03, Figure 4.12). In addition, in univariate survival analysis, miR-23a-3p over-
expression resulted significantly associated with poor PFS (p-value<0.01, HR=1.8), whereas it did 
not show a significant correlation with OS. More interestingly, multivariate Cox regression analysis, 
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revealed miR-23a-3p up-regulation, along with tumor residual, significant correlated with shorter 
PFS (p-value=0.01, HR=1.78).  
 
Table 4.9: HRMs emerged significantly differentially expressed in HGSOC vs normal tissues, by 
microarray analysis. miR-23a-3p and miR-27a-3p showed a borderline (p-value=0.056) and 
significant (p-value=0.036) association with platinum-resistant tumors. 
 
Tissue HRMs 
HGSOC vs Control Resistant vs Sensitive 
Log FC  Aver. Expr. p-value 
Adj. 
p-value Log FC 
Aver. 
Expr. p-value 
Adj. 
p-value 
hsa-miR-210 1.377 7.868 0.0001 0.0001 0.037 8.009 0.85 0.907 
hsa-miR-24-3p 1.451 10.244 0.0001 0.0001 -0.006 10.462 0.959 0.959 
hsa-miR-23a-3p 2.076 10.017 0.0001 0.0001 0.361 10.311 0.007 0.056 
hsa-miR-27a-3p 2.795 9.749 0.0001 0.0001 0.435 10.151 0.002 0.036 
hsa-miR-21-5p 2.028 13.02 0.0001 0.0001 0.069 13.246 0.739 0.892 
hsa-miR-23b-3p 1.303 9.344 0.0001 0.0001 -0.161 9.561 0.424 0.679 
hsa-miR-26b-5p -1.449 9.354 0.0001 0.0001 0.104 9.161 0.485 0.706 
hsa-miR-103a-3p -0.826 10.068 0.0001 0.0001 0.13 9.96 0.335 0.67 
hsa-miR-107 -1.319 9.505 0.0001 0.0001 0.069 9.323 0.622 0.829 
hsa-miR-192-5p -1.413 4.851 0.0001 0.0001 -0.067 4.719 0.78 0.892 
hsa-miR-93-5p -1.319 8.625 0.0001 0.0001 -0.232 8.47 0.114 0.305 
hsa-miR-181b-5p 1.249 5.604 0.0001 0.0001 0.146 5.762 0.389 0.679 
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Figure 4.11: Significant over-expression of selected HRMs in 99 HGSOC compared to 25 normal 
tissues. Data are displayed as mean ± SD and are expressed normalized for SNORD48. 
 
                     
Figure 4.12: Significant over-expression of miR-23a-3p in 40 platinum-resistant compared to 36 
platinum-sensitive patients. Data are displayed as mean ± SD and are expressed normalized for 
miR-191-5p. 
p-value=0.03 
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HGSOC 
Control 
Control 
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4.2.9 Evaluation of HRMs in cancer stem cell-like (CSC) line 
Starting from a primary ovarian cancer cell line OVA-BS4, established in our laboratory after sterile 
processing of a surgical metastatic high-grade serous tumor biopsy, under selective culture 
conditions, we isolated OVA-BS4 parent cell line formed non-adherent spheres, potentially 
enriched in cells with stem-like properties. This cell line has been extensively characterized in our 
laboratory by molecular and phenotypic characterization, that revealed a stem-like phenotype. 
More interestingly, OVA-BS4 spheres showed resistance to all the traditional anti-cancer agents 
tested (cisplatin, paclitaxel, etoposide, PS341, doxorubicin and trabectedin) compared to the 
parental OVA-BS4 adherent cell line. Starting from these evaluations, we decided to test miR-210, 
miR-23a-3p, miR-24-3p and miR-27a-3p in OVA-BS4 spheres with CSC-like properties, as a 
reliable in-vitro model of chemo-resistance. Three independent biological replicates were tested by 
RT-qPCR, using SNORD48 as miRNA expression normalizer, showing the lowest coefficient of 
variation among samples. In all three cases, mir-210 expression was consistently increased in 
OVA-BS4 spheres compared to OVA-BS4 adherent cell line (Figure 4.13). Although the scanty 
number of samples evaluated did not allow to reach a significant statistical difference between the 
two conditions, a noticeable trend of up-regulation of miR-210 emerged from the comparison 
(p=0.07). On the contrary, the other three HRMs analyzed did not show any evident differential 
expression between conditions. 
 
                 
 
Figure 4.13 Expression of selected HRM miR-210 in OVA-BS4 spheres and in OVA-BS4 parental 
cell line. Data are displayed as mean ± SD of three independent experiments and are normalized 
using SNORD48. 
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4.2.10 Target prediction 
Using TargetScan , we looked at identifying putative mRNA targets of miR-23a-3p, the hypoxia-
related miRNA emerged significantly up-regulated in HGSOC patients and, more interestingly, in 
the group of patients resistant to platinum-based chemotherapy, compared to platinum-sensitive 
patients. An anti-correlation miRNA/mRNA pairs analyses was performed, based on gene and 
miRNA expression levels obtained by microarray. Thousands of genes emerged as potential 
targets of miR-23a-3p (data not shown). In particular, among the gene at the top of the list, 
showing the best value of anti-correlation, we identified APAF-1. This gene, coding for the 
apoptotic protease activating factor-1, plays a crucial role in the regulation of apoptosis, and it has 
been already demonstrated as potential target of miR-23a-3p in other types of solid tumors.  
 
4.3 Discovery of HGSOC specific long non-coding RNAs 
From RNA sequence data analysis, we identified a total of 1371 transcripts, differentially expressed 
between platinum-resistant (n=14) and platinum-sensitive patients (n=14) (data not shown). Only 
125 out of 1371 transcripts (9%) were already known sequences, associated to coding or non-
coding genes. Most of the transcripts detected (n=539, 39%) represented potentially novel 
isoforms of reference transcripts and almost 147 (11%) sequences showed a generic overlap with 
noted transcripts. Moreover, the data analysis identified 139 (10%) unknown, intergenic transcripts 
and 389 (28%) exonic transcripts overlapped with reference sequences on the opposite strand. 
Finally, almost 32 transcripts (3%) were due to read mapping errors. Interestingly, a very small part 
of the collected transcriptional alterations can be ascribed to coding-genes, suggesting a prominent 
non-coding role in HGSOC platinum resistance. Currently, we are validating a panel of ten selected 
transcripts to confirm our method of analysis.  
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5. DISCUSSION 
Circulating miRNA as potential diagnostic markers in HGSOC 
HGSOC represents the most lethal gynecologic malignancy, with survival rate virtually unchanged 
in the past 30 years. HGSOC high mortality reflects its asymptomatic nature, the lack of adequate 
screening test, the low predictive capacity of diagnosis in an early stage and the development of 
resistance to the standard therapies. The possibility to identify the early onset of HGSOC is thus of 
extreme importance for improving patients’ clinical outcome. Studies performed so far have 
confirmed the limits of currently used diagnostic biomarkers, like CA-125, to identify early phases 
of tumor growth and disseminated disease [Jacobs IJ et al 2016; Terry KL et al 2016]. Considering 
the lack of ovarian cancer screening tests able to significantly reduce the mortality of patients, the 
development of novel strategies for early diagnosis, such as the identification of novel biomarkers, 
is one of the possible strategies to pursue.  
Conceptually, there are different steps for a molecule to be selected as a biomarker, along the path 
from the bench to patient’s bedside. Starting from these premises, in the first part of my PhD 
project, we aimed at identifying, in sera of patients, molecular features of tumor biology that could 
represent one step forward in the identification of novel biomarkers for early disease detection. In 
the last years, there has been a growing interest in the potential role of circulating miRNAs as 
diagnostic biomarkers in different types of carcinoma, including ovarian cancer. Indeed, a blood-
based test can be easy accessible, minimally invasive and it could represent a promising screening 
test for early disease detection. In recent years, several circulating miRNAs have been identified as 
biomarkers with implications in ovarian cancer diagnosis. However, there is a lack of consensus in 
the normalization strategy of circulating miRNA levels exists in the literature, mainly due to the 
absence of reliable “reference miRNAs”. Therefore, despite the relative abundance of published 
papers, the vast majority of them reveals a hastily data standardization and a normalization 
performed in a suboptimal way, using reference miRNAs arbitrarily chosen among those most 
commonly published. Moreover, most previously studies analyzed circulating miRNAs belonging to 
patients harbouring all ovarian carcinoma histotypes, while the few investigations focused on 
HGSOC specific miRNAs in serum/plasma are limited by a narrow sample size. Finally, RT-qPCR 
is the most reported technique for studying miRNA expression in biological fluids, while a high-
throughput system is more desirable when reliable markers need to be discovered. In summary, 
many technical challenges in the analysis of circulating miRNAs (i.e., samples storage and 
processing, profiling methods and data normalization) have complicated the comparison of 
independent datasets and delayed their entering into clinical settings.  
To overtake the several issues described above, my study focused into an experimental design 
that displays several improved features compared to other studies, including: i) serum samples 
belonging to patients harbouring HGSOC, the most frequent and aggressive ovarian cancer 
histological type, ii) two cohorts of patients, gathered from independent serum collections, that 
were used to obtain molecular data, reducing biases in statistical analysis, iii) serum from age-
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matched healthy women as normal controls, iv) optimized protocol including collection, handling, 
storage and miRNAs extraction of serum samples, v) haemolysis monitoring of serum samples, vi) 
the use of an innovative and effective statistical approach of microarray data normalization, 
combining synthetic spike-in RNA oligos and the most invariant endogenous miRNAs, vii) the use 
of two RT-qPCR techniques for miRNA validation and, in particular, of Exiqon primer sets with LNA 
technology, which maximizes sensitivity and specificity in detecting miRNA amplicons. According 
to the aforementioned critical issues, we used microarray technology on a total of 110 serum from 
HGSOC patients and 19 healthy volunteers to achieve an efficient selection of the most promising 
miRNAs among the thousands of possible candidates sourced from the miRNome (miRBAse 
version 19). In addition, we developed a novel bioinformatic approach to identify specific circulating 
miRNAs characterizing HGSOC patients. In particular, we chose to apply an innovative approach 
of statistical analysis, using the expression levels of 10 different non-human spike-in oligos, 
combined with a set of most invariant low-expressed endogenous miRNAs, to normalize circulating 
miRNA levels. 
The miRNA profile on the training set initially allowed us to identify 97 miRNAs with different 
expression levels between HGSOC patients and healthy controls. Among miRNAs selected for RT-
qPCR validation, miR-1246, miR-595, miR-4290, miR-2278 confirmed to be significantly up-
regulated in the HGSOC patients group compared to healthy donors. Importantly, the up-regulation 
of miR-1246, miR-595 and miR-2278 was furtherly validated by RT-qPCR in a completely 
independent dataset of serum samples, obtained from 58 HGSOC and 13 healthy donors. 
Moreover, since miR-1246 has emerged as the most reliable biomarker, we performed an absolute 
quantification of circulating miR-1246 copies using ddPCR, validating once more its significantly 
differential expression between the two groups of samples. Notably, we performed ROC curve 
analysis on miR-1246 to estimate its sensitivity and specificity, as diagnostic performance for 
HGSOC detection. Our findings confirmed miR-1246 as the most promising diagnostic biomarker, 
as it was able to accurately classify tumor patients compared to healthy donors, both in the training 
and in the validation cohorts. To the best of our knowledge, miR-1246 has not been associated to 
ovarian cancer previously, neither at the tissue nor at the serum levels. Nevertheless, its 
expression has been largely reported as upregulated in other cancer tissues, such as lung, oral, 
colorectal, esophageal, hepatic, pancreatic and cervical carcinoma [Kim G et al 2016; Liao L et al 
2015; Wang S et al 2016; Fu HL et al 2013; Sun Z et al 2014; Hasegawa S et al 2014; Chen J et al 
2014]. As circulating marker, miR-1246 has been proposed, alone or in combination with others, 
for the detection of multiple myeloma, oesophageal, colon, cervical carcinomas and early stage 
breast cancer [Jones CI et al 2012; Takeshita N et al 2013; Ogata-Kawata H  et al 2014; Chen J et 
al 2013; Shimomura A et al 2016]. Furthermore, high levels of circulating miR-1246 and miR-595 
have been reported associated to active forms of inflammatory bowel disease [Krissansen GW et 
al 2015].  
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Gene and miRNA expression in HGSOC compared to normal tissues  
HGSOC is often an incurable gynecological malignancy. Although the majority of tumors initially 
respond to chemotherapy, most patients succumb to chemoresistant recurrent disease. Despite a 
variety of cytotoxic anti-cancer agents and targeted therapy such as bevacizumab have recently 
emerged, control over the progression of HGSOC remains inadequate. Chemoresistance is the 
principal factor limiting long-term survival in ovarian carcinoma patients. Currently available 
prognostic parameters are not able to adequately predict HGSOC relapse and clinical course. 
Therefore, the need to discover novel accurate outcome-informative markers would be critical to 
select those patients who could benefit from individualized therapies. The lack of reliable 
prognostic markers and the lack of effective therapies for patients with HGSOC in some way 
reflects the incomplete understanding of the molecular basis of its pathogenesis and progression. 
In this context, the recent identification of the regulatory role of non-coding RNAs (ncRNAs) 
extended the spectrum of possible key factors involved in essential biological processes of cancer 
development and progression. Starting from these premises, in the second part of my PhD project, 
we performed a global RNA expression profiling, including coding and ncRNAs, such as miRNAs 
and lncRNAs, in order to better understand the transcriptional and post-transcriptional mechanisms 
characterizing HGSOC. In particular, we have attempted to identify molecular markers to 
adequately predict HGSOC relapse and clinical course. Gene and miRNA expression profiles have 
been reported as associated with overall survival, primary surgical cytoreduction (debulking 
status), and response to platinum therapy in ovarian cancer [Crijns AP et al 2009; Bonome T et al. 
2008; Jazaeri AA et al. 2005; Cancer Genome Atlas Research Network 2011]. Despite those 
encouraging developments, no biomarker for prediction of response to therapy has been clinically 
useful yet. The particular design of my study has been characterized by several features, including: 
i) a wide and well-characterized cohort of snap-frozen tumor tissue samples of high grade serous 
histological type, the most frequent and aggressive ovarian cancer, belonging to a single 
institution, ii) the inclusion of both ovarian surface and fallopian tube epithelia, as source of normal 
control tissues, to better understand the histogenesis of HGSOC, still debated, iii) a stringent 
quality control of isolated total RNA, iv) a genome wide RNA expression analysis, including 
mRNA/miRNA/lncRNA signature, by high-throughput microarray Agilent Technology®, v) the 
careful selection of putative reference sncRNAs, for an accurate quantification of miRNA levels by 
RT-qPCR, vi) the use of optimized Exiqon primer sets with LNA technology, maximizing sensitivity 
and specificity in amplicon detection, vii) the possibility to match tumor biopsies and serum 
samples from the majority of patients enrolled in the study. 
In this study, we performed a comprehensive gene and miRNA expression profiling on a cohort of 
99 advanced-stage HGSOC patients, partially matched with serum samples (n=76) and 16 healthy 
controls, obtained both from normal ovary and luminal fallopian tube surface epithelia. By 
microarray analysis, most of the genes and miRNAs have emerged aberrantly expressed in 
HGSOC tissue samples. After filtering steps, by microarray technology a total of 265 miRNAs (123 
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upregulated and 142 downregulated) have emerged significantly differentially expressed between 
HGSOC and normal tissues. To potentially clarify  the HGSOC precursor, we performed a principal 
component analysis on miRNA expression profile, including all the HGSOC tissues of our cohort 
and the potential neoplasm precursors, obtained both from HOSEs and fallopian tube epithelium 
brushing. The analysis was based on the most variable miRNAs (n=200) among the three different 
types of tissues. Interestingly, this miRNA profile analysis was able to cluster our samples in three 
different and clearly separated groups. More importantly, luminal fallopian tube epithelium miRNA 
profile shared a higher similarity to HGSOC miRNA profile, compared to ovarian surface epithelium 
one. This preliminary result seems to unlock new insights on HGSOC biogenesis, supporting a 
recent novel theory on the origin of this aggressive tumor [Kurman RJ et al. 2010].  
 
Gene, miRNA and lncRNA expression according to response to platinum-based chemotherapy in 
HGSOC 
Within our large and uniform records, we examined the association of gene expression profile with 
chemotherapy status of patients. Using the whole platform of genes examined, unsupervised 
analysis did not generate any cluster able to differentiate patients according to chemotherapy 
status. However, the comparison between the group of platinum-resistant and platinum-sensitive 
patients identified Homer Protein Homolog 2 (HOMER2) as the only differentially expressed gene. 
This gene encodes a member of the homer family of dendritic proteins; members of this family 
regulate group 1 metabotrophic glutamate receptor function. In our cohort of samples, HOMER2 
showed a down-regulation in the group of chemo-resistant patients. This gene is known in the 
literature to cooperate with a class myosin MYO18B and their co-expression enhances the ability 
of MYO18B to suppress the anchorage-independent growth of a human lung cancer cell line [Ajima 
R et al. 2007].  
Based on high-throughput gene expression analysis, we performed a topological-based pathway 
analysis, using Graphite Web, a novel web tool developed by Sales et al [Sales G et al. 2013]. This 
method, combining topological and multivariate pathway analyses, allows identifying significant 
signal transduction paths within significantly altered pathways. Moreover, since a biological 
pathway is not a mere list of genes, but represents the biologic relations between genes, in this 
analysis, each gene can contribute to the statistical significance of the pathway with a final additive 
effect due to its interaction with the other genes within the network. Particularly, the gene set 
analysis on our cohort of HGSOC samples revealed a total of 58 pathways involved in the 
mechanism of platinum-resistance. Among them, we identified Tight junction, Erb signaling, Wnt 
signaling, Cell cycle, Jak/STAT signaling and cell adhesion molecules pathways. Some interesting 
pathways, among the differentially expressed, have been already reported contributing to the onset 
of resistance to therapy and warrant to be further investigated [Anastas JN et al. 2013, Ma J et al. 
2014]. 
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According to response to platinum-based chemotherapy and prognosis, we identified a total of 9 
differently expressed miRNAs (miR-199b-5p, miR-423-5p miR-455-3p, miR-22-3p, miR-199a-3p, 
miR-15b-5p, miR-140-5p, miR-1246, miR-320c) in the group of patients platinum-resistant and 
partially platinum-sensitive compared to platinum-sensitive patients, and significantly associated 
with overall survival and progression free survival. Since the up-regulation of circulating miR-1246 
levels in HGSOC patients has been confirmed by three different techniques (microarray, RT-qPCR 
and ddPCR) and since miR-1246 up-regulation in HGSOC biopsies was associated with platinum-
resistance and worse prognosis by microarray analysis, we focused on the validation of its 
expression in our cohort of tumor and normal tissues by RT-qPCR.  
Currently, there is no literature consensus on the most stably expressed endogenous controls that 
should be used in HGSOC miRNA RT-qPCR studies. Similarly to mRNA expression analysis, the 
choice of reference genes for miRNA RT-qPCR data normalization has a great impact on the study 
outcome, as different normalization strategies can lead to different interpretation of data resulting in 
ambiguous biological conclusions [Calin GA et al. 2006]. As already postulated, miRNA may act “in 
cascade” over several mRNA genes, regulating multiple target within the same pathway, thus small 
changes in miRNA expression could have important consequences for a given cellular function 
[Mestdagh P et al. 2014]. Accordingly, the validation of endogenous normalizers is even more 
critical for miRNA RT-qPCR experiments, considering that relatively small differences in miRNA 
expression may be biologically and clinically significant. Then, before proceeding with miRNA 
expression level validation by RT-qPCR, we identified the most suitable small non coding RNAs 
(sncRNAs) as endogenous controls for miRNA expression normalization in a subset of HGSOC 
samples and normal tissues. Eleven putative reference sncRNAs for normalization (U6, 
SNORD48, miR-92a-3p, let-7a-5p, SNORD61, SNORD72, SNORD68, miR-103a-3p, miR-423-3p, 
miR-191-5p, miR-16-5p) and miR-26a-5p and miR-1249, emerged as the most invariant miRNAs 
by our microarray analysis, were analyzed using a highly specific RT-qPCR. Combining results 
from three different statistical approaches, SNORD48 emerged as stably and equivalently 
expressed between malignant and normal tissues. Among malignant samples, considering groups 
based on residual tumor, miR-191-5p was identified as the most equivalents ncRNA. It was not 
surprising to find miR-26a-5p and miR-1249 not further confirmed as the most invariant miRNAs in 
our cohort of HGSOC and normal tissues, using RT-qPCR. It is well known that hybridization 
platform, such as microarray technology, has a lower sensitivity and specificity compared to 
quantitative PCR (qPCR), that represents the gold standard for single miRNA measurement. For 
all miRNA quantifications performed in this study by RT-qPCR on tissues, we decided to apply the 
Exiqon technology, that quantify miRNA expression in a two-step PCR process of modified RT-
PCR, followed by a qPCR. In particular, starting from total RNA, a universal transcription system 
provided template for all mature miRNAs, overcoming the need for miRNA-specific RT whose 
efficiency can vary among different miRNAs. Both PCR amplification primers were miRNA-specific 
and chemically modified in the ribose mojety of nucleotides to stabilize the conformation of the 
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sugar groups, according to the Exiqon technology. The conformation of locked nucleic acid (LNA) 
oligos resulted in enhanced hybridization properties and increased sensitivity and specificity in 
detection of scnRNAs. Moreover, the RT mechanism allowed the amplification of mature miRNA 
only, without amplification of pre-miRNA whose interaction with oligos is prevented by the 
presence of the loop. The exceptional sensitivity, specificity and accuracy of the Exiqon RT-qPCR 
system have recently been confirmed by Mestdagh and colleagues in the widest peer-reviewed 
investigation of microRNA profiling platforms performed to date [Mestdagh P et al. 2014]. Then, 
based on our results, using SNORD48 as normalizer, we confirmed the downregulation of miR-
1246 expression levels in HGSOC samples compared to HOSEs, by RT-qPCR. Interestingly, we 
did not detect a significantly differential expression between HGSOC compared to fallopian tubes. 
This result mirrors the previously reported global miRNA expression trend emerged by our 
microarray analysis, where luminal fallopian tube surface epithelium miRNA profile appears more 
similar to tumor miRNA profiles compared to ovarian surface epithelium one.  
According to platinum response, miR-1246 showed a significantly increased expression in the 
group of chemoresistant compared to sensitive patients. Importantly, miR-1246 over-expression 
was significantly associated with poor OS and with shorter PFS in HGSOC patients by RT-qPCR. 
Moreover, we showed that miR-1246 over-expression represents an independent prognostic factor 
for OS and PFS in HGSOC patients. This result is in line with the aforementioned studies, where 
miR-1246 overexpression was correlated with poor patient survival in several type of cancers [Liao 
L et al 2015, Hong L et al 2013, Hasegawa S et al 2014]. Moreover, recently, several miR-1246 
target mRNAs and related pathways have been identified and validated. In particular, miR-1246 
has been associated with stemness in non-small cell lung cancer and reported to be involved in 
tumor metastasis by targeting CPEB4 mRNA [Kim G et al. 2016]. This association with cancer 
stem cells (CSCs) has been also described in pancreatic carcinoma, where miR-1246 negatively 
regulates CCNG2 mRNA and promotes resistance to chemotherapy [Hasegawa S et al. 2016]. The 
inhibition of CCNG2 induced by miR-1246 was described also in colorectal cancer, contributing to 
a more aggressive tumor phenotype [Wang S et al. 2016]. In hepatocarcinoma cell lines, miR-1246 
enhanced migration and invasion by down-regulation of CADM1 gene and it is supposed to be 
regulated by p53, leading to suppression of cellular proliferation by targeting NFIB [Sun Z et al. 
2014]. Finally, Chen et al reported that miR-1246 promotes proliferation, invasion and migration 
through the inhibition of its target gene THBS2 in cervical carcinoma [Chen J et al. 2014]. 
In the last part of the study with the aim to discover new coding and non-coding variants of known 
transcripts or totally novel transcripts, associated with the mechanism of resistance, we have 
sequenced the entire transcriptome of HGSOC tumor biopsies belonging to 14 platinum-sensitive 
and 14 platinum-resistant patients. The transcriptome reconstruction of the 28 sequencing 
experiments allowed us to identify 1371 transcripts differentially expressed between pt-resistant 
and pt-sensitive samples. Among them, 125 transcripts showed a complete match of intron chain 
with known transcripts, while 686 were potentially novel isoforms or showed a generic overlap with 
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known transcripts. The remaining, if validated, could be novel intergenic transcripts or transcripts 
with an exonic overlap with reference ones. Interestingly, a very small part of the collected 
transcriptional alterations can be ascribed to coding-genes, suggesting a prominent non-coding 
role in HGSOC platinum resistance. Further validation is necessary to better define the functional 
and predictive/prognostic role of the detected transcriptional alterations.  
 
Comparison of miRNA expression profiles between matched serum and tissue samples 
An important issue addressed in our study deals with the comparison between miRNA expression 
pattern observed in serum and in matched cancer tissues. Our results strengthen that, although 
both the HGSOC serum and tissue samples showed dysregulated global miRNA profile compared 
to normal counterpart, they did not show high correlation to each other. This discrepancy suggests 
the hypothesis that the circulating miRNA profiling is a contribute of tumor-specific and 
inflammation-specific miRNAs, or that miRNA could be released or captured in microvesicles and 
exosomes acting as a novel mechanism of genetic exchange between cells. Our findings are in 
line with previous reports on several solid cancers, where only 7% of the serum and tissue-derived 
signatures displayed excellent concordance in a discovery setting [Jarry J et al. 2014]. 
 
Hypoxia-regulated miRNAs in HGSOC  
Tumor microenvironment, in particular the low O2 tension that improves the tumor 
neovascularization, contributes to the onset of chemoresistance during HGSOC progression. 
Recently, a group of miRNAs, termed hypoxia regulated-miRNAs (HRMs), has been identified as 
key elements in response to hypoxia, regulating mechanisms that confer a more aggressive tumor 
phenotype. The complexity of hypoxia molecular mechanisms has not yet been fully elucidated in 
HGSOC, therefore there is an urgent need to discover novel biomarkers clinically useful to select 
patients with hypoxic tumors that may benefit of tailored treatments. In this context, we focused our 
analysis on a group of 16 miRNAs belonging to the group of HRMs emerged from literature as 
relevant in other solid tumors. Most of the HRMs showed a significant differential expression in 
HGSOC compared to normal tissues by microarray analysis. Among them, miR-210, being the 
most widely studied miRNA associated with hypoxia and considered a master miRNA of the 
hypoxic response, was selected for further validations. Additionally, we validated miR-23a-3p and 
miR-27a-3p, showing a significant and a borderline significant association with poor overall survival 
respectively by microarray analysis, and miR-24-3p located on the same miR-23a-3p/27a-3p gene 
cluster. RT-qPCR confirmed the over-expression of all the four HRMs tested in HGSOC compared 
to normal tissues, suggesting the presence of hypoxia areas within the HGSOC masses. miR-23a-
3p over-expression was confirmed in platinum-resistant patients, highlighting the importance of 
hypoxia in HGSOC mechanism of drug resistance. More interestingly, we demonstrated miR-23a-
3p over-expression as a novel prognostic factor for HGSOC patients, significantly correlated with 
worse PFS. Furthermore, we verified the expression of these four miRNAs in our cancer stem cell-
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like (CSC) line, exhibiting resistance to all the traditional anti-cancer agents tested. Among them, 
miR-210 showed a borderline significant up-regulation in cancer stem cell-like line, compared to 
parental adherent cell line. Therefore, these preliminary results warrant further investigations to 
demonstrate the implication of HRMs and, in particular of miR-210, in chemoresistance 
mechanisms. Previous studies have already investigated the expression and involvement of these 
HRMs in several types of cancer. In particular, miR-27a-3p has been found to promote 
proliferation, migration and invasion in osteosarcoma cells by targeting MAP2K4 [Pan W et al. 
2014]. Moreover, miR-27a-3p has been shown to induce esophageal cancer cell proliferation by 
FBXW7 suppression [Wu XZ et al. 2015]. Interestingly, in a study conducted on neuronal cell, miR-
23a-3p and miR-27a-3p have been shown to alleviate hypoxia-induced neuronal apoptosis, 
suppressing Apaf-1 [Chen Q et al 2014]. Similarly, miR-23a-3p has been found to regulate Apaf-1 
protein activity, in both pancreatic ductal adenocarcinogenesis and colorectal cancer [Liu N et al. 
2015; Yong FL et al. 2014]. In line with these results, our target prediction analysis, using an anti-
correlation microRNA/mRNA pairs, based on gene and miRNA expression profiles obtained by 
microarray analysis on the entire cohort of HGSOC and controls, revealed Apaf-1 at the top of 
mRNA anti-correlated to miR-23a-3p. Apaf-1 (Apoptotic protease activating factor 1) is a 
cytoplasmatic protein that plays a central role in the apoptosis regulatory network. If further 
validated, this result might explain a potential role of miR-23a-3p as oncogene, that contributes via 
Apaf-1 suppression to apoptosis inhibition and, consequently to confer chemoresistance to 
HGSOC cells.  
 
Summary and future perspectives 
In summary, during my PhD study, I mainly focused on the analysis of circulating miRNAs in 
HGSOC patients, as potential diagnostic biomarkers. Particularly, we optimized a reliable protocol 
to extract miRNAs from serum samples and to generate miRNA profiles with microarray 
technology. Our results indicate that there are specific miRNAs significantly differentially expressed 
in HGSOC patients compared to controls. The application of a robust method of statistical 
normalization, based on the use of nine different exogenous spike-in oligos and the most invariant 
endogenous miRNAs, allowed us to identify specific HGSOC circulating miRNAs with potential 
impact as diagnostic biomarkers. In particular, miR-1246 emerged as the most consistently up-
regulated miRNA in the serum of HGSOC patients compared to healthy donors, as assessed by 
three independent technologies (microarray, RT-qPCR and ddPCR) and validated in two 
independent cohorts of patients. To the best of our knowledge, this is the first study demonstrating 
miR-1246 as a potential diagnostic serum biomarker in HGSOC. Prospective studies on larger 
cohort of serum samples are warranted to validate the performance of miR-1246 in HGSOC 
diagnosis. Future perspectives will include, firstly, the analysis of miR1246 in the serum of patients 
with benign serous cystoadenomas, in order to evaluate its diagnostic performance in 
discriminating malignant from benign disease. Secondly, we plan to assess miR-1246 as potential 
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biomarker in monitoring tumor response to treatment, taking advantage of longitudinal serum 
samples, collected during patient follow-up, already present in our biobank.  
In the second part of the study, I focused on the generation of a miRNA/mRNA/lncRNA signature 
characterizing HGSOC tissues, on a wide and well-characterized group of patients, partially 
matched with the serum sample cohort (n=76). As normal counterpart, we have collected sixteen 
controls from normal ovary (HOSE) and luminal fallopian tube surface epithelia, both representing 
the hypothesized origin of HGSOC, whose histogenesis is still a matter of debate. Our preliminary 
results contribute to the recent theory that fallopian tube could represent the most likely HGSOC 
precursor, showing a higher similarity in miRNA profile between HGSOC and luminal fallopian tube 
epithelium, compared to HOSE. 
High-throughput analysis on HGSOC tissues and normal controls generated a huge amount of 
data, still to be examined in detail. So far, by microarray analysis, most of the genes and miRNAs 
have emerged significantly differentially expressed between HGSOC and normal samples. 
The miRNA profile analysis will be integrated with gene and lncRNA expression profiles in order to 
increase the comprehension of the mechanisms involved in HGSOC histogenesis and to 
potentially identify novel predictive and prognostic biomarkers. 
In this regard, our preliminary analysis on miRNA expression profile in platinum-resistant vs 
platinum-sensitive patients revealed the involvement of miR1246 in the mechanism of drug 
response and prognosis. Indeed, its overexpression by microarray, further confirmed by RT-qPCR, 
emerged significantly associated with chemoresistance and worst prognosis in HGSOC patients. 
As a corollary of our main study, since there is a lack in the literature regarding reliable reference 
for relative quantification in miRNA expression studies, we experimentally identified SNORD48 as 
the best reference sncRNA between HGSOC and normal controls. In addition, miR-191-5p has 
emerged as best reference sncRNA among HGSOC tissues. 
Taken together, our results obtained both at the serum and tissue levels have highlighted the 
crucial role of miR-1246 in HGSOC development and chemoresistance. To further strengthen our 
hypothesis, we evaluated miR-1246 expression in an ovarian cancer stem cell-like (CSC) line, a 
model of in-vitro chemo-resistance, established in our laboratory under selective culture conditions. 
Interestingly, we have found a significantly miR-1246 overexpression in CSCs compared to 
parental adherent cell line by RT-qPCR (result not reported in the thesis). These preliminary results 
deserve further investigations, such as the evaluation of the functional role of miR-1246 in 
chemoresistance mechanisms, using in-vitro assays. 
Among miRNAs resulted differentially expressed by microarray analysis, a group of hypoxia-
regulated miRNAs (HRMs) emerged  significantly over-expressed in HGSOC samples compared to 
normal counterpart, suggesting an important implication of miRNAs in response to hypoxic 
condition. Specifically, we have hypothesized the involvement of miR-23a-3p in chemoresistance 
mechanism, through APAF-1 inactivation. Further in-vitro studies are necessary to confirm these 
preliminary results and to explore the numerous mechanisms in which these miRNAs could be 
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involved in drug response. In this context, we planned to firstly evaluate HRM expression in our 
chemoresistance CSC model and in several primary HGSOC cell lines established in our 
laboratory. Secondly, we are going to treat these cell lines with cobalt chloride (CoCl2) in order to 
mimic the hypoxic condition within the tumor, and then to investigate the functional role of HRMs. 
Finally, data emerged from RNA sequencing preliminary analysis revealed a prominent role of non-
coding transcripts in HGSOC platinum resistance mechanisms. Currently, we are validating a 
panel of ten transcripts, to confirm our method of analysis. These data will be integrated with gene 
and miRNA expression profiles previously obtained, with the aim to identify tumor circuits 
associated with response to treatment and prognosis, as well as to better elucidate the molecular 
mechanisms characterizing HGSOC progression and adaptation to hypoxic tumor 
microenvironment. Importantly, the identification of specific HGSOC pathways could lead to the 
individuation of novel molecular target for cancer therapy and for the personalization of treatment 
regimens. For instance, at present, the mutational status of genes involved in the homologous 
recombination (HR) DNA repair, as in particular BRCA1 and BRCA2, both at germline and somatic 
level, is a key determinant of platinum sensitivity in HGSOC patients, and provides a rational basis 
for the use of PARP inhibitors in first line treatment. In this context, we are currently performing 
targeted sequencing of a panel of selected genes involved in HR DNA repair on our cohort of 
HGSOC tissues, in order to better characterize their genomic profile and to correlate it to response 
to treatment and prognosis. 
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6. CONCLUSIONS 
In conclusion, miR-1246 emerged as the most consistently up-regulated miRNA in the serum of 
HGSOC patients compared to healthy donors, as assessed by three independent technologies 
(microarray, RT-qPCR and ddPCR) and validated in two independent cohorts of patients. To the 
best of our knowledge, this is the first report demonstrating miR-1246 as a potential diagnostic 
serum biomarker in HGSOC.  
At tissue level, most of the genes and miRNAs have emerged significantly differentially expressed 
between HGSOC and normal samples, by microarray analysis. Interestingly, luminal fallopian tube 
miRNA expression profile showed a higher similarity to HGSOC miRNA profile, compared to 
HOSE. This result strengthens the recent novel theory that fallopian tube could represent the most 
likely HGSOC precursor. Moreover, our results indicate, for the first time, that miR-1246 over-
expression correlates with a platinum-resistant HGSOC phenotype and may constitute a novel 
independent prognostic factor for HGSOC patients. 
Regarding hypoxia-regulated miRNAs, our findings suggest an important role of miRNAs in 
response to hypoxic conditions within HGSOC masses. In particular, miR-23a-3p over-expression 
in chemoresistance patients may contribute to explain the importance of hypoxia in HGSOC 
mechanism of drug resistance and could represent a novel independent prognostic factor for this 
neoplasm. 
Finally, preliminary analysis of RNA sequencing showed a prominent expression of non-coding 
transcripts in HGSOC platinum resistance mechanisms. These data will be integrated with gene 
and miRNA expression profiles previously obtained, with the aim to identify tumor circuits 
associated with response to treatment and prognosis, as well as to better elucidate the molecular 
mechanisms characterizing HGSOC progression and adaptation to hypoxic tumor 
microenvironment. 
Taken together, these observations strongly support the crucial role that non-coding RNAs play in 
HGSOC development and drug response. In this context, the identification of specific HGSOC 
networks of gene regulation could lead to the individuation of novel molecular targets for cancer 
therapy and to the personalization of treatment regimens.  
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8. SUPPLEMENTARY MATERIALS 
8.1 Serum Microarray Data Analysis: filtering and normalizations 
Serum raw microarray data comprised 1361 miRNAs (included controls and spikes) repeated 40 
times. The expression of these 40 replicates per miRNA have been used as technical replicates 
and quality control. A first filter has been applied to select those miRNAs with reliable expression 
values within arrays. Specifically, within each experiment we selected only miRNAs with at least of 
20% good quality measures among the 40 replicates (using gisPosandSig Agilent flag), otherwise 
they were considered NA (not available). Then, a second filter was applied among arrays. 
Specifically, we selected only miRNAs with at least 75% of good quality measures (not NA) across 
samples. After these filtering steps, we remain with 648 miRNAs (including the 10 spikes). Then 
the miRNA replicates within samples were summarised using the median. The small amount of 
missing values still present after the filtering step was imputed with k-nearest neighbourhood 
method. The distributions of the raw expression values are reported in the first panel of 
Supplementary Figure S1. 
As expected, spikes raw measurements are characterised by high expression and large variability. 
In principle, after normalization we would expect i) that spikes distribution were stable on high 
expression levels across samples and with low variability and ii) that the boxplot of expression 
values of the experiments should be centered in mean. To identify the best normalization 
technique we performed a comparative evaluation using different algorithms: quantile [Bolstad BM 
et al. 2003], variance stabilising normalization (vsn) [Geller SC et al. 2003] and classic cyclic loess 
[Bolstad BM et al. 2003] and custom cyclic lowess in which spike-in controls are used as stabilising 
factors. Specifically, we applied two types of modified loess: i) the first in which the local regression 
parameters are estimated using only spikes genes (CLWs); ii) the second in which the local 
regression parameters are estimated using both spikes and a set of 20 selected invariant low 
expressed genes (CLWsin). Invariant low expressed miRNAs have been selected as miRNAs with 
expression values less than 3 (in log scale) and with the smallest difference in mean between 
cases and controls. Normalised expression distributions with different normalization methods are 
reported in Supplementary Figure S1.  
miRNA serum expression distributions are characterised by a very skew distribution towards small 
values (that is, a distribution with a large number of very small expression values and few number 
of highly expressed values). Thus, the use of only spikes (characterised by large expression 
values) as normalizing factors leads to a bias transformation of the data towards large expression 
values. This bias is evidenced in Supplementary Figure S1 were the lowess normalization using 
only spikes leads to highly heterogeneous boxplots. However, in this context, an appropriate set of 
normalising factors should contain both high and low expressed invariant features. For this reason, 
as well as spikes, we included, in the set of normalizing factors, 20 invariant low expressed 
miRNAs (different number of invariant miRNAs have been used from 10 to 30 but with small 
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differences in performance, data not shown). As shown in Supplementary Figure S1, the 
application of this last strategy leads to the best compromise between stable distribution of spikes 
expression values across samples and centered arrays boxplot. 
Another basic plot to verify the goodness of a normalization is the Relative Log Expression (RLE) 
plot. The RLE plot shows the distribution of the ratio between the expression of a miRNA and the 
median expression of this miRNA across all arrays of the experiment. It is assumed that most 
miRNAs are not changed across the arrays, so it is expected that these ratios are around 0 on a 
log scale. The boxplots presenting the distributions should then be centered near 0 and have 
similar spread. Other behaviour would be a sign of low quality. The RLE plots obtained after each 
normalization were reported in Supplementary Figure S2. As expected by construction classic 
loess, quantile and vsn have more homogeneous RLEs, but a wrong distribution of spikes. 
However, lowess with weight on spikes and low invariant genes has the best compromise between 
a stable distribution of spike expression and homogeneous distribution of RLE plots. Then we 
decide to use this approach as the best in our case.  
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Supplementary Figure S1: Distribution of the raw and normalised expression values with 
highlighted spike-in data. The type of normalization is reported on the right gray bar of each 
panel. 
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Supplementary Figure S2: RLE plots of expression data after normalization. The type of 
normalization is reported on the right gray bar. 
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Supplementary Table S1: List of 97 circulating miRNAs emerged significantly differentially 
expressed between HGSOC patients vs healthy donors by microarray technology (those in bold 
were selected for validation).  
rank microRNA adjust ρ-value 
Mean log2 expression 
log Fold Change 
Control Case 
1 hsa-miR-483-3p 0,0000 3,42 4,45 1,04 
2 hsv2-miR-H6-3p 0,0000 2,50 3,02 0,52 
3 hsa-miR-1290 0,0000 3,60 4,60 1,01 
4 hsa-miR-1224-3p 0,0000 2,61 3,15 0,54 
5 hsa-miR-4290 0,0000 3,10 4,06 0,96 
6 hsa-miR-328 0,0002 3,15 3,76 0,60 
7 hsv1-miR-H1-3p 0,0002 2,71 3,27 0,57 
8 hsa-miR-129-2-3p 0,0002 2,66 3,13 0,47 
9 hsv1-miR-H6-3p 0,0002 3,03 3,92 0,89 
10 hsa-miR-485-3p 0,0003 2,69 3,24 0,55 
11 hsa-miR-4284 0,0004 3,37 4,05 0,67 
12 hsa-miR-595 0,0004 3,54 5,03 1,49 
13 hsa-miR-664a-3p 0,0004 2,57 2,92 0,35 
14 ebv-miR-BART16 0,0004 3,43 4,97 1,54 
15 hsa-miR-2278 0,0005 3,19 4,41 1,22 
16 hcmv-miR-US4 0,0007 3,64 3,11 -0,54 
17 hsa-let-7b-3p 0,0007 2,95 3,69 0,74 
18 hsa-miR-32-3p 0,0008 3,73 5,19 1,46 
19 hsa-miR-3147 0,0008 3,90 3,17 -0,72 
20 hsa-miR-365a-3p 0,0008 3,10 3,69 0,59 
21 hsa-miR-129-1-3p 0,0008 2,65 3,06 0,41 
22 hsv2-miR-H9-3p 0,0008 2,76 3,31 0,55 
23 hsa-miR-4323 0,0008 2,73 3,28 0,55 
24 hsa-miR-3148 0,0008 3,23 4,57 1,34 
25 hsa-miR-615-3p 0,0008 2,50 2,84 0,35 
26 hsa-miR-766-3p 0,0008 3,49 4,07 0,57 
27 hsa-miR-3675-3p 0,0008 2,60 3,10 0,49 
28 hsa-miR-3149 0,0011 3,69 5,14 1,45 
29 hsa-let-7f-1-3p 0,0011 3,18 3,87 0,69 
30 hsa-miR-92b-3p 0,0016 2,49 2,93 0,44 
31 hsa-miR-1825 0,0016 4,18 5,02 0,84 
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32 hsa-miR-211-5p 0,0021 2,67 2,94 0,28 
33 hsa-miR-3613-3p 0,0026 2,59 3,11 0,52 
34 hsa-miR-1180 0,0026 2,75 3,80 1,05 
35 ebv-miR-BART12 0,0026 3,67 4,94 1,27 
36 hsa-miR-1228-5p 0,0032 2,84 3,89 1,05 
37 hsa-miR-4312 0,0039 2,74 3,20 0,46 
38 hsa-miR-634 0,0046 2,68 3,03 0,35 
39 hsa-miR-127-3p 0,0046 2,75 3,38 0,63 
40 hsa-miR-877-3p 0,0046 3,46 4,21 0,75 
41 
hsa-miR-3647-
3p_v17.0 
0,0057 2,75 3,42 0,67 
42 hsa-miR-2277-3p 0,0059 3,11 3,52 0,41 
43 hsa-miR-576-5p 0,0061 2,68 2,90 0,21 
44 hsa-let-7f-2-3p 0,0063 2,57 2,74 0,18 
45 hsa-miR-539-5p 0,0064 2,75 3,44 0,69 
46 hsa-miR-670 0,0065 3,00 4,06 1,06 
47 hsa-miR-609 0,0067 2,58 2,83 0,26 
48 hsa-miR-3676-3p 0,0073 2,82 3,47 0,65 
49 hsa-miR-449c-3p 0,0073 2,53 2,93 0,40 
50 hsa-miR-1246 0,0077 6,24 7,18 0,94 
51 hsa-miR-3180-5p 0,0087 2,59 3,03 0,44 
52 hsa-miR-3679-3p 0,0087 2,90 3,22 0,32 
53 hsa-miR-1539 0,0109 2,82 3,48 0,66 
54 ebv-miR-BART4-5p 0,0111 2,75 3,40 0,66 
55 hsa-miR-2116-3p 0,0117 2,79 3,41 0,62 
56 hsa-miR-613 0,0125 2,41 2,69 0,27 
57 hsa-miR-299-5p 0,0132 2,51 2,77 0,27 
58 hsa-miR-505-3p 0,0135 2,54 2,73 0,19 
59 hsa-miR-337-3p 0,0146 2,71 2,97 0,26 
60 hsa-miR-656 0,0146 2,48 2,71 0,22 
61 hsa-miR-933 0,0146 3,01 3,47 0,47 
62 hsa-miR-18b-3p 0,0150 2,60 2,97 0,38 
63 hsa-miR-4313 0,0151 3,32 4,07 0,75 
64 hsa-miR-574-5p 0,0154 5,83 7,27 1,44 
65 hsa-miR-1237-3p 0,0156 2,75 3,22 0,47 
66 hsa-miR-4310 0,0164 2,85 3,52 0,66 
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67 hsa-miR-23c 0,0164 2,90 3,48 0,59 
68 
ebv-miR-BART10-
3p 
0,0169 2,60 3,27 0,67 
69 hsa-miR-1306-3p 0,0172 2,81 3,60 0,79 
70 hsa-miR-329 0,0176 2,52 2,76 0,24 
71 hsa-miR-425-3p 0,0191 2,96 3,58 0,62 
72 hsv1-miR-H7-3p 0,0191 3,45 3,97 0,51 
73 hsa-miR-4281 0,0218 10,50 11,37 0,87 
74 hsa-miR-181a-5p 0,0218 3,58 3,14 -0,44 
75 hsa-miR-133a 0,0218 2,50 2,76 0,26 
76 
kshv-miR-K12-12-
5p 
0,0218 2,59 2,97 0,39 
77 ebv-miR-BART3-5p 0,0218 2,68 3,23 0,55 
78 
ebv-miR-BART10-
5p 
0,0218 2,57 2,77 0,19 
79 hsa-miR-3907 0,0223 2,76 3,35 0,59 
80 hsa-miR-631 0,0240 2,48 2,72 0,23 
81 hsa-miR-937-3p 0,0247 2,50 2,80 0,30 
82 hsa-miR-320a 0,0247 5,19 4,46 -0,73 
83 hsa-miR-133b 0,0247 2,56 2,77 0,21 
84 hsa-miR-885-5p 0,0271 2,73 3,08 0,35 
85 hsa-miR-106b-5p 0,0271 5,45 4,79 -0,66 
86 kshv-miR-K12-8-5p 0,0299 2,62 2,94 0,32 
87 hsa-miR-1281 0,0323 4,99 5,69 0,70 
88 hsa-miR-297 0,0365 2,56 3,03 0,47 
89 hsa-miR-195-3p 0,0407 2,75 3,50 0,75 
90 hsa-miR-602 0,0414 2,71 3,15 0,44 
91 hsa-miR-454-5p 0,0429 2,66 2,96 0,30 
92 
ebv-miR-BART17-
3p 
0,0469 2,44 2,71 0,26 
93 dmr_31a 0,0476 10,04 10,53 0,49 
94 hsa-miR-191-3p 0,0476 3,36 3,93 0,57 
95 hsa-miR-1972 0,0476 2,67 3,06 0,39 
96 hsa-miR-3650 0,0476 2,52 2,98 0,47 
97 hsa-miR-206 0,0476 2,71 3,55 0,84 
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8.2 miR-15b normalization strategy 
To further validate our data, we identified miR-15b as a putative reference miRNA, resulting to be 
the most invariant in our cohort of samples (Supplementary Figure S3), as well as in others 
reported in the literature [Bianchi F et al. 2011]. Using delta-Ct method and miR-15b as reference, 
we normalized the expression levels of candidate miRNAs across all HGSOC samples and healthy 
controls. As shown in Supplementary Table S2, miR-1246 and miR-595 were also successfully 
validated by this further normalization approach, either in training set or in validation cohort of 
samples. miR-4294 maintained its opposite trend. On the contrary, miR-2278 confirmed its 
differential expression level between HGSOC and controls in the training set (p<0.0001), while not 
in the validation set (p=0.461). Therefore, it was excluded from further validations. 
 
 
Supplementary Figure S3: Boxplot of the miR-15b Ct values for both training and validation sets.  
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Supplementary Table S2:  Expression levels of nine selected miRNA, normalized according to 
miR-15b, evaluated by RT-qPCR in the sera of two independent cohorts of HGSOC and healthy 
donors 
RT-qPCR 
Training set  Validation set  
Control Case Control Case 
miR-1246 
median (ΔCT) 
[IQR] 
0.963 
[0.089] 
0.859 
[0.075] 
 
0.959 
[0.031] 
 
0.907 
[0.058] 
 
mean (ΔCT) 
[sd] 
0.957 
[0.057] 
 
0.868 
[0.066] 
 
0.953 
[0.042] 
 
0.910 
[0.047] 
 
p-value (2-ΔCT) 0.0000 0.0041 
miR-574-5p 
median (ΔCT) 
[IQR] 
1.014 
[0.092] 
 
1.038 
[0.101] 
 
1.072 
[0.045] 
 
1.039 
[0.061] 
 
mean (ΔCT) 
[sd] 
1.022 
[0.064] 
 
1.038 
[0.074] 
 
1.081 
[0.045] 
 
1.039 
[0.054] 
 
p-value (2-ΔCT) 0.1768 0.0068 
miR-483-3p 
median (ΔCT) 
[IQR] 
1.207 
[0.094] 
 
1.222 
[0.112] 
 
1.128 
[0.049] 
 
1.129 
[0.062] 
 
mean (ΔCT) 
[sd] 
1.200 
[0.074] 
 
1.214 
[0.083] 
 
1.124 
[0.051] 
 
1.133 
[0.052] 
 
p-value (2-ΔCT) 0.3256 0.5754 
miR-4290 
median (ΔCT) 
[IQR] 
1.208 
[0.094] 
 
1.186 
[0.108] 
 
1.059 
[0.027] 
 
1.083 
[0.072] 
 
mean (ΔCT) 
[sd] 
1.221 
[0.080] 
 
1.191 
[0.081] 
 
1.055 
[0.042] 
 
1.093 
[0.058] 
 
p-value (2-ΔCT) 0.0270 0.0132 
miR-595 
median (ΔCT) 
[IQR] 
1.267 
[0.118] 
 
1.220 
[0.135] 
 
1.193 
[0.057] 
 
1.148 
[0.094] 
 
mean (ΔCT) 
[sd] 
1.265 
[0.084] 
 
1.227 
[0.107] 
 
1.197 
[0.057] 
 
1.155 
[0.073] 
 
p-value (2-ΔCT) 0.0098 0.0268 
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miR-2278 
median (ΔCT) 
 
 
[IQR] 
1.342 
[0.146] 
 
1 257 
[0.100] 
 
1.170 
[0.043] 
 
1.180 
[0.059] 
 
mean (ΔCT) 
[sd] 
1.354 
[0.114] 
 
1.260 
[0.091] 
 
1.167 
[0.034] 
 
1.176 
[0.047] 
 
p-value (2-ΔCT) 0.0000 0.4605 
miR-32-3p 
median (ΔCT) 
[IQR] 
1.333 
[0.100] 
 
1.357 
[0.100] 
 
1.337 
[0.076] 
 
1.293 
[0.112] 
 
mean (ΔCT) 
[sd] 
1.336 
[0.082] 
 
1.370 
[0.086] 
 
1.360 
[0.112] 
 
1.307 
[0.079] 
 
p-value (2-ΔCT) - - 
miR-4281 
median (ΔCT) 
[IQR] 
1.436 
[0.116] 
 
1.362 
[0.099] 
 
1.328 
[0.102] 
 
1.307 
[0.088] 
 
mean (ΔCT) 
[sd] 
1.433 
[0.094] 
 
1.368 
[0.085] 
 
1.336 
[0.066] 
 
1.319 
[0.072] 
 
p-value (2-ΔCT) - - 
miR-3148 
median (ΔCT) 
[IQR] 
1.443 
[0.174] 
 
1.391 
[0.149] 
 
1.335 
[0.104] 
 
1.343 
[0.081] 
 
mean (ΔCT) 
[sd] 
1.460 
[0.109] 
 
1.382 
[0.117] 
 
1.318 
[0.082] 
 
1.348 
[0.074] 
 
p-value (2-ΔCT) - - 
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